Protocol I5B -MC-JGDM (c) 
 
Title:  A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients with Potentially 
Resectable Soft Tissue Sarcoma T reated with Olaratumab Monother apy Followed by [CONTACT_831424] 02783599  
 
Approval Date: 08 -May-2017  
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 1
LY3012207Approval Date: 1.Protocol I5B -MC-JGDM (c)
A Phase 1b Trial to A ssess the Modulation of Biological 
Markers in Patients with Potentially  Resectable Soft Tissue
Sarcoma Treated with Olaratumab Monotherapy  Followed 
by [CONTACT_831425].  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_831409] (LY3012207) , unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries.   This document and its associated 
attachments are subject to [LOCATION_002] Freedom of Information Act (FOIA) Exemption 4.
Olaratumab (LY3012207)
Study I5B -MC-JGDM is an open -label, single -arm, multicenter, multicountry Phase 1b 
study to enumerate whole blood circulating tumor cells and to characterize platelet -derived 
growth factor receptor alpha, platelet -derived growth factor receptor beta and canonical 
ligands (PDGF -A, B, C , and D)expression changes pre -and post -olaratumab monotherapy 
in tumor tissue inpatients with potentially resectable soft tissue sarcoma .
Eli Lilly and Company
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]
Protocol Electronically Signed and Approved by [CONTACT_11007]: 02 March 2016
Amendm ent (a) Electronically Signed and Approved by [CONTACT_11007] : 25 May 2016
Amendm ent (b) Electronically Signed and Approved by [CONTACT_11007] :  26 Jul 2016
Amendm ent (c) Electronically Signed and Approved by [CONTACT_57968]:
Approval Date: 08-May-2017 GMT
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 2
LY30122072.Synopsis
This Phase 1b study  is an open -label, single -arm, mul ticenter, m ulticountry  study  to enum erate 
whole blood circulat ing tumor cells and to characterize platel et-derived growth factor receptor
alpha, platelet-derived growth factor receptor beta,and canonical lig ands (PDGF -A, B, C ,andD)
expressio n changes pre -and post -olaratum ab m onotherapy  in tum or tissue inpatients with 
potenti ally resectable soft ti ssue sarco ma.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 3
LY30122073.Table of Contents
A Phase 1b Trial to A ssess the Modulation of Biological 
Markers in Patients wi th Potentially  Resectable Soft Tissue 
Sarcoma Treated with Olaratumab Monotherapy  Followed by  
[CONTACT_831426]
1. Protocol  I5B-MC-JGDM(c)  A Phase 1b Trial to Assess the 
Modulation of Bio logical Markers in Pat ients with Potenti ally 
Resectable Soft Tissue Sarco ma Treated with Olaratumab 
Monotherapy  Followed by [CONTACT_831427] .......................................................................................................... [ADDRESS_1153946] to Follow -Up................................................................................... 29
6.3.4. Discontinuati on of  Study  Sites............................................................................. 29
6.3.5. Discontinuati on of  the Study ................................................................................ 29
7. Treatment .......................................................................................................................... 30
7.1. Materi als and Supplies .................................................................................................30
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 4
LY30122077.1.1. Packaging and Labelling ...................................................................................... 30
7.1.2. Olaratum ab.......................................................................................................... 30
7.1.3. Doxorubi cin......................................................................................................... 31
7.2. Study Drug Administration .......................................................................................... 31
7.2.1. Treatments Administered ..................................................................................... 31
7.2.2. Prem edicat ion...................................................................................................... 32
7.2.3. D ose Modificat ions.............................................................................................. 33
[IP_ADDRESS]. Dose Delays, Modificat ions, and Discont inuat ions......................................... 33
[IP_ADDRESS].1. Olaratum ab............................................................................................... 35
[IP_ADDRESS].1.1. Infusio n-Related Reactions .................................................................35
[IP_ADDRESS].1.2. Hem atologic Toxi city.......................................................................... 36
[IP_ADDRESS].1.3. Nonhematologic Toxicit y.................................................................... 37
[IP_ADDRESS].2. Doxorubi cin.............................................................................................. 37
[IP_ADDRESS].2.1. Hem atologic Toxi city.......................................................................... 37
[IP_ADDRESS].2.2. Cardi ovascular Toxi city...................................................................... 38
[IP_ADDRESS].2.3. Hepati c Impairment............................................................................. 38
[IP_ADDRESS].2.4. Nonhematologic Toxicit y.................................................................... 39
7.3. Method of Assignment to Treatment ............................................................................ 39
7.3.1. Selection and Timing o f Doses ............................................................................. 39
7.4. Blinding ....................................................................................................................... 39
7.5. Concomita nt Therapy ................................................................................................... 39
7.5.1. Supportive Care ................................................................................................... 40
[IP_ADDRESS]. Dexrazoxane ................................................................................................... 40
[IP_ADDRESS]. Granulocyte -Colony St imulat ing Factors and Erythro id 
Growth Factors ............................................................................................... 40
[IP_ADDRESS]. Transfusio n of Blood Products ........................................................................ 41
[IP_ADDRESS]. Anti-emet ic Therapy ....................................................................................... 41
7.5.2. Prohibited Therapi[INVESTIGATOR_014] ............................................................................................ 41
[IP_ADDRESS]. Effect of CYP3A4, CYP2D6, and P -gp Inhibitors and 
Inducers on Doxorubicin ................................................................................ [ADDRESS_1153947] ion......................................................................................................................... 43
8.1. Safety Evaluat ions........................................................................................................ 43
8.1.1. Safety Data Collection and Review ...................................................................... 43
8.1.2. Adverse Events .................................................................................................... 43
[IP_ADDRESS]. Serious Adverse Events .................................................................................. 44
[IP_ADDRESS]. Adverse Event and Serious Adverse Event Reporting ..................................... 45
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 5
LY30122078.[IP_ADDRESS]. Prior to Administrati on of  Study  Drugs ..................................................... 45
[IP_ADDRESS].2. On Study  Treatm ent.................................................................................. 45
[IP_ADDRESS].3. Follow-Up Vi sit........................................................................................ 46
[IP_ADDRESS]. Suspected Unexpected Serious Adverse React ions.......................................... 46
[IP_ADDRESS]. Summary  of AE/SAE Reporti ng Guidelines ................................................... 46
8.1.3. Other Safet y Measures ......................................................................................... 47
[IP_ADDRESS]. Electrocardiograms ......................................................................................... 47
[IP_ADDRESS]. Echocardi ograms /MUGA Scans ..................................................................... 48
8.1.4. Safety Moni toring ................................................................................................ 48
[IP_ADDRESS]. Adverse Events of Special Interest .................................................................. [ADDRESS_1153948] ing..................................................................................... 50
8.2.1. Samples for Study  Qualificat ion and Healt h Monit oring ....................................... 50
8.2.2. Samples for Drug Concentration Measurements 
Pharmacokinet ics.................................................................................................50
[IP_ADDRESS]. Pharmacokinet ic Samples ............................................................................... 50
8.2.3. Samples for Bi omarkers ....................................................................................... 51
[IP_ADDRESS]. Blood S amples................................................................................................ 52
[IP_ADDRESS]. Tumor Ti ssue .................................................................................................52
[IP_ADDRESS]. Imaging Studi es.............................................................................................. 54
8.2.4. Samples for Pharmacogenet ics............................................................................. 54
8.2.5. Samples for Immunogenicit y Research .................................................................54
8.3. Efficacy Evaluations .................................................................................................... 54
8.4. Procedure/Sampling Co mpliance .................................................................................. 55
9. Data Management Methods ............................................................................................... 56
9.1. Data Qualit y Assurance ................................................................................................ 56
9.2. Data Capture Systems .................................................................................................. 56
9.2.1. Case Report Form ................................................................................................ 56
9.2.2. Ancillary  Data ...................................................................................................... 57
10. Data Analyses ................................................................................................................... 58
10.1. Gene ral Considerati ons ................................................................................................ 58
10.1.1. Determinat ion of Sample Size .............................................................................. 58
10.1.2. Analysis Populat ions............................................................................................ 59
10.2. Patient Disposi tion....................................................................................................... 59
10.3. Patient Characteri stics.................................................................................................. 59
10.4. Safety Analyses ............................................................................................................ 59
10.5. Biomarker Analyses ..................................................................................................... 60
10.6.Efficacy
........................................................................................................................ 60
I5B-MC-JGDM (c)Phase [ADDRESS_1153949] igator Informat ion....................................................................................... 63
11.3.2. Protocol  Signatures .............................................................................................. 63
11.3.3. Final Report Signature ......................................................................................... 63
12. References ........................................................................................................................ 64
I5B-MC-JGDM (c)Phase [ADDRESS_1153950] of Tables
Table Page
Table JGDM.1. Treatment Regimens ...................................................................................... 32
Table JGDM.2. General Guidelines for Olaratumab Dose Modification Due to 
Hem atologic Toxi city Deemed Related to Olaratumab ................................... 36
Table JGDM.3. General Guidelines for Olaratumab Dose Modification Due to 
Nonhematologic Toxicit y Deemed Related to Olaratumab ............................. 37
Table JGDM.4. General Guidelines for Doxorubicin Dose Modification Due to 
Neutropenia ................................................................................................... 38
Table JGDM.5. Adverse Event and Serious Adverse Event Reporting Guidelines ................... 47
Table JGDM.6. Bazett’s QT Heart Rate Correction Formula .................................................. 48
Table JGDM.8.3 Fridericia’s QT Correcti on Form ula............................................................... 48
I5B-MC-JGDM (c)Phase [ADDRESS_1153951] of Figures
Figure Page
Figure JGDM.1. Illustrati on of  study  design. ............................................................................ 26
I5B-MC-JGDM (c)Phase [ADDRESS_1153952] Criteria ................................................................... 84
Attachm ent 9. Protocol  JGDM CYP3A4, CYP2D6, and P -gp Inhibitors and Inducers 
of Doxorubi cin.............................................................................................. 91
Attachm ent 10. Protocol  JGDM Protocol Amendment I5B -MC-JGDM(c) Summary:  A 
Phase 1b Trial to Assess the Modulat ion of Bio logical Markers in 
Patients wi th Potenti ally Resectable Soft Ti ssue Sarcom a Treated wi th 
Olaratum ab Monotherapy  Followed by  [CONTACT_831428] .................................................................................... 93
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 10
LY30122074.Abbreviations and Definitions
Term Definition
AE adverse event:  Any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product thatdoes not 
necessarily have a causal relationship with this treatment.  An adverse event 
(AE) can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with 
the use of a medici nal (investigational) product, whether or not related to the 
medicinal (investigational) product.
AESI adverse event of special interest
ALT alanine aminotrans ferase
ANC absolute neutrophil count
ASCO American Society of Clinical Oncology
AST aspartate aminotrans ferase
AUC (0-tlast) area under the plasma concentration -time curve from time zero to the last 
measurable plasma concentration
AUC (0-∞) area under the plasma concentration -time curve from time zero to infinity
audit A systematic and independent examination of the study -related activities and 
documents to determine whether the evaluated study -related activities were 
conducted, and the data were recorded, analyzed, and accurately reported 
according to the protocol, applicable standard o perating procedures (SOPs), 
good clinical practice (GCP), and the applicable regulatory requirement(s).
BE1 biomarker evaluable 1
BE2 biomarker evaluable 2
C1D1 Cycle 1 Day  1
C1D8 Cycle 1 Day  8
C2D1 Cycle 2 Day  1
C2D8 Cycle 2 Day  8
C3D1 Cycle 3 Day  1
CI confidence interval
CIOMS Council forInternational Organizations ofMedical Sciences
CL clearance
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 11
LY3012207CLRM clinical laboratory results modernization
Cmax maximum plasma concentration
Cmin minimum plasma concentration
CNS central nervous system
collection database A computer database where clinical trial data are entered and validated.
complaint Any written, electronic, or oral communication that alleges deficiencies related 
to the identity, quality, purity, durability, reliability, safety, effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory requirements.
confirmation A proces s used to confirm that laboratory test results meet the quality 
requirements defined by [CONTACT_365188].  Confirmation will either occur immediately 
after initial testing or will requ ire that samples be held to be retested at some 
defined time point, depending on the steps required to obtain confirmed results.
CR complete response
CRu complete response unconfirmed
CRF/eCRF case report form/electronic case report form:  Sometimes ref erred to as clinical 
report form, a printed or electronic form for recording study participants’ data 
during a clinical study, as required by [CONTACT_760].
CRP clinical research physician
CRS clinical research scientist
CT computed tomography
CTC circulating tumor cell
CTCAE Common Terminology Criteria for Adverse Events
CYP cytochrome P450
DCR disease control rate
DCSI Development Core Safety Information
ECG electrocardiogram
ECHO echocardiogram
ECOG Eastern Cooperative Oncology Group
EDTA ethylenediaminetetraacetic
I5B-MC-JGDM (c)Phase [ADDRESS_1153953] signed the informed 
consent form directly or through their legally acceptable representatives.
ERB/IRB ethical review board/institutional review board:  /A board or committee 
(institutional, regional, or national) composed of medical and nonmedical 
members whose responsibility is to verify that the safety, welfare, and human 
right s of the patients participating in a clinical study are protected.
GCP good clinical practice
G-CSF granulocyte colony stimulating factor
GIST gastrointestinal stromal tumors
HR hazard ratio
IB Investigator’s Brochure
ICF informed consent form
ICH International Conference on Harmonisation
IG immunogenicity
IgG1 immunoglobulin G, subclass 1
IHC immunohistochemistry
informed consent A process by [CONTACT_9444] a patient voluntarily confirms his or her willingness to 
participate in a particular trial, after having been informed of all aspects of the 
trial that are relevant to the patient’s decision to participate.  Informed consent 
is documented by [CONTACT_3553] a written, signed and dated informed consent form.
interim analysis An analy sis of clinical study data that is conducted before the final reporting 
database is authorized for datalock.
IRR infusion -related reaction
I5B-MC-JGDM (c)Phase [ADDRESS_1153954] (IP)A pharmaceutical form of an active substance or placebo being tested or used as 
a reference in a clinical trial .  Investigational product includes a product with a 
marketing authorization w hen:
1.used or assembled (formulated or packaged) in a way different from 
the authorized form
2.used for an unauthorized indication or
3.used to gain furth er information about the authorized form
investigator A person responsible for the conduct of the clinical study at a study site.  If a 
study is conducted by a team of individuals at a study site, the investigator is the 
responsible leader of the team and may be called the principal investigator.
ITT intent -to-treat
IV intravenous(ly)
IWRS Interactive Web Response System
legal 
representativeAn individual, judicial, or other body authorized under applicable law to 
consent o n behalf of a prospective patient, to the patient’s participation in the 
clinical study.
Lilly Safety System Global safety database that tracks and reports serious adverse and spontaneous 
events occurring while using a drug/drug delivery system.
LMS leiomyosarcoma
LVEF left ventricular ejection fraction
MAPK mitogen -activated protein kinase 
MedDRA Medical Dictionary for Regulatory Activities
MOA mechanism of action
monitor A person responsible for ensuring the investigator site complies with the 
monitoring plan, applicable local standard operating procedures (if any), and 
global Medical standard operating procedures.  Monitors are trained on the 
investigational product(s), t he protocol, informed consent document, any other 
written information provided to subjects, relevant standard operating 
procedures, International Conference on Harmonisation Good Clinical Practice 
guidelines, and all applicable laws (for example, privacy a nd data protection) 
and regulations. 
mOS median overall survival
MRI magnetic resonance imaging
MUGA multi-gated acquisition
NCCN Natio nal Comprehensive Cancer Network
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 14
LY3012207NCI Natio nal Cancer Institute
open -label A study  in which there are no restrictions on knowledge of treatment allocation; 
therefore, the investigator and the study participants are aware of the drug 
therapy  received during the study.
ORR objective response rate
patient A subject with a defined disease.
PD progressive disea se 
PDGF platelet -derived growth factor
PDGFRα platelet -derived growth factor receptor alpha
PDGFRβ platelet -derived growth factor receptor beta
PET positron emission tomography
PFS progression -free survival
P-gp P-glycoprotein
PK pharmacokinetic(s)
PR partial response
PS performance status
QTc corrected QT interval
QTcF Fridericia’s QT corrected interval
RECIST Response Evaluation Criteria in Solid Tumors
Resectability Evaluatio n of the resectability of a tumor is determined by [CONTACT_831429] -disciplinary team, and depends on the tumor stage 
and the patient’s co -morbidity .  The primary aim of surgery is to completely 
excise the tumor with a margin of normal tissue.
reporting database A point -in-time copy of the collection database.  The final reporting database is 
used to produce the analyses and output reports for interim or final analyses of 
data.
re-screen to screen a patient who was previously declared a screen failure for the same 
study
SAE serious adverse eve nt
I5B-MC-JGDM (c)Phase [ADDRESS_1153955] of determining if an individual meets minimum requirements to become 
part of a pool of potential candidates for participation in a clinical trial.  In this 
study, screening involves invasive or diagnostic procedures and/or tests (for 
example, diagnostic psychological tests, x -rays, blood draws).  For this type of 
screening, informed consent for these screening procedures and/or tests shall be 
obtained; this consent may be separate from obtaining consent for the study.
screen failure A patient who does not meet one or more criteria required for participation in a 
trial
SD stable disease
sponsor The party who takes responsibility for the initiation, management and/or 
financing of a clinical study.
STS soft tissue sarcoma
study comple tion This study will be considered complete once Lilly determines that the 
evaluations of the primary objective and safety are sufficient and complete.
S[LOCATION_003]R suspected unexpected serious adverse reaction
t1/[ADDRESS_1153956] upper limit of normal
Vd volume of distribution
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 16
LY3012207A Phase 1b Trial to A ssess the Modulation of Biological 
Markers in Patients with Potentially  Resectable Soft Tissue 
Sarcoma Treated with Olaratumab Monotherapy  Followed by  
[CONTACT_831430]
5.Introduction
5.1. Rationale and Justification for the Study
Soft tissue sarco ma (STS) is a heterogeneous group of tumors that arise mainly fro m embry onic 
mesoderm, with so me neuroectodermal contribution and different iation to non -epi[INVESTIGATOR_240176], fat, and fibrous tissue (D’Angelo et al. 2014).  There are 
approximately  50 tum or subty pes of  STS (Sharm a et al . 2013) and they  can be l ocated anywhere 
in the body .  Soft tissue sarco mais rare , com prising approximately 1% of adult cancers .The
annual incidence of STS in the United Kingdo m and [LOCATION_002] is 3300 and 10,000, 
respectively  (Jemal et al . 2009; NCIN [WWW] ).  Soft ti ssue sarco ma is best treated by  
[CONTACT_831431] t he management of these tumors (Linch et al. 2014). 
When the disease is localized, it is usually treated with curative intent using surgical resect ion 
with or wi thout radiotherapy  and/orchemotherapy.  Unfortunately, STS recurs frequent ly as 
locally inoper able or m etastati c disease, at which t ime systemic therapy plays a prominent role in 
the multidisciplinary management of this tumor .  Single -agent doxorubi cin is st ill considered the 
standard treatment option for many pat ients with metastati c STS (NCCN 201 1; ESMO 2014; 
Scho ffski et al. 2014) and has also been used in the pre -operative setting (NCCN 2016) .  
Previously  reported data support edthe advancement of olaratumab (IMC -3G3, LY3012207) in 
later phase human trials, including Eli Lilly and Company (Lilly) ’s Phase 1b/2 rando mized Phase 
2 Study  I5B-IE-JGDG (JGDG) , which evaluated the efficacy and safet yof doxorubicin wit h or 
without ol aratumab in advanced STS.  Patients treated with olaratum ab and doxorubi cinin the 
Phase 2 portion of this study , com pared to those treated with single -agent doxorubi cin, achieved 
a higher m edian progressi on-free survival ( PFS; 6.[ADDRESS_1153957] ively [stratified 
hazard ratio (HR) =0.672 (95% confidence interval [CI]:  0.442, 1.021 ); p = 0.0615] ),median 
overall survival (m OS; 26.5 vs. 14.7 m onths , respectively [stratified HR =0.463 (95% CI :  
0.301, 0.710 ); p = 0.0003]) and object ive response rate (ORR ; 18.2% vs. 11.9% , respectively ; 
p= 0.3421 ), with an acceptable and monitorable safet y profile. 
The efficacy of o laratumab in this STS pati entpopulat ion provi des an important opportunit y to 
more fullycharacteri ze the mechanism of act ion (MOA) of olaratum ab.
Olaratum ab is a recombinant human immunoglobulin G, subclass 1 (IgG1) antagonist of the 
platelet-derived growth factor receptor alpha ( PDGFR , which has been demonstrated to play 
an important role in mesenchymal bi ology,and in modulat ing the tumor and stromal 
microenvironment.  Preliminary a nalysis of tum or specimens fro m Study  JGDG indicated that 
tumor expressio n of PDGFR receptor by  [CONTACT_9064] ( IHC)did not predi ct 
improvement in mOS. Possible explanat ions for this finding include the highly  variable and 
often lengthy time periods between tumor sampling and study  entry , the analysis of primary 
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 17
LY3012207versus metastatic lesio ns, and inco mplete understanding of the level of PDGFR receptor and 
ligand expressio n in tum or and strom a needed for efficacy .
For these reasons, this study  will enroll  patients with potentially resectable STS, to allow pre-
and post -olaratumab dosing tumor sampling of the same primary  tumor lesion, while also 
provi ding the potential  opportuni ty to examine a resected tumor specimen after combinat ion 
treatm ent wi th olaratumab and doxorubicin. 
Platelet-derived growth factor receptor alpha activation leads to the activat ion of several well -
characterized downstream signaling cascades including the Ras/mitogen -activated protein kinase 
(MAPK) pathway , the phosphat idylino sitol 3-kinase pathway , and the phospholipase C -ɣ [ADDRESS_1153958]  in sarco mas(Shah et al . 2010).  Increased expressio n of PDGFR αhas been described in 
epi[INVESTIGATOR_831410] -mesenchymal transit ion (EMT) (Jechlinger et al. 
2006).  The EMT state is associated with increased invasiveness and metastasis (Thiery et al. 
2009).  Autocrine signaling via PDGFR αin association with Ras oncogenic mutati on is 
positively correlated with metastasis in a murine breast cancer line (Jechlinger et al. 2006).  Non -
canonical act ivation of PDGFR αprom otes bone metastasis of prostate cancer cells, and 
inhibit ion of PDGFR αin prostate cancer suppresses tumor angioge nesis and growth of skeletal 
metastases (Dolo ff et al. 2007 ;Russell et al . 2009 , 2010; Park et al . 2011). Given this growing 
body  of literature, the abilit y of o laratumab to disrupt sarcoma metastasis will be invest igated in 
Study  I5B-MC-JGDM (JGDM).
The predilect ionfor sarcom as to spread hematogenously provide rationale for using a whole 
blood “liquid biopsy” approach for enum eration and characterizat ion of circulat ing sarco ma 
tumor cells pre -and posttreatment with olaratumab to invest igate the role o f olaratum ab in 
disrupt ing the metastatic potential o f sarco mas.  Using serial pre-and posttreatment who le blood 
samples, the proposed study  will invest igate the effects of olaratumab (as monotherapy and in 
combinat ion with doxorubi
cin) on ci rculat ing tumor cell (CTC) counts .  The who le blood 
samples may  also be used for exploratory  analyses and further molecular characterizat ion.
The sponsor (Lilly) , monitor, and invest igators will perform this study  in compliance wit h the 
protocol , good clinical practice (GCP) and Internatio nal Conference on Harmonisat ion (ICH) 
guidelines, and applicable regulatory  requi rements.
5.2. Objectives
5.2.1. Primary Objective s
The primary  object ivesof this study  are:
to enumerate CTCs changes pre -and post -olaratumab m onotherapy  in who le 
blood in pat ients with potenti ally resectable STS .
tocharacterize PDGFR and platelet-derived growth factor receptor beta 
(PDGFR )and canonical ligands ( PDGF -A, B, C ,and D) expressio n changes 
pre-and post -olaratumab m onotherapy  in tum or tissue in patients wi th 
potenti ally resectable STS.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 18
LY30122075.2.2. Secondary Objectives
The secondary  objectives o f this study  are:
to evaluate any ant itumor activit y observed wi th olaratum ab:
oprogression -free survival ( PFS)and 3 -month PFS 
oORR (com plete response [CR] + partial response [PR])
odisease control  rate (DCR) (CR+ PR + stable disease [SD] )
orate of resectabilit y.
to evaluate the safet y of olaratum ab as assessed by [CONTACT_187031], clinical 
laboratory  tests, vi tal signs, physical examinat ions, el ectrocardi ograms
(ECGs) , and echocardiograms (ECHOs) or multi-gated acqui sition (MUGA) 
scans .
to evaluate the pharmacokinet ics (PK) of olaratumab and immunogenicit y 
(IG) parameters of olaratumab.
5.2.3. Exploratory Objective s
The exploratory  objectives of this study  are:
to evaluate blood, CTCs ,andtumor tissue pre-and post -therapy  for
biomarkers related to pathways associated with STS, the MOA of olaratumab, 
cancer -related condi tions, and/or immune cells/immune and tumor 
microenvironment functioning wit hin the disease state and/or cancer -related 
condi tions. 
to assess the relationship between biomarker expressio n at baseline ,and 
change from baseline, and clinical outcomes.
5.3. Genera lIntroduction to Olaratumab
Olaratum ab is a recombinant human IgG1- type m onoclonal ant ibody  that binds to PDGFRα.  
This antibody  possesses high affinit y bindi ng for PDGFRα and blocks platelet- derived growth 
factor (PDGF )-AA, -BB, and -CC from binding to the receptor.  In addit ion to bl ocking ligand-
induced cell mitogenesis and receptor autophosphorylat ion, olaratumab inhibits ligand -induced 
phosphorylat ion of t he downstream signaling mo lecul es Akt and MAPK (Loizos et al. 2005; 
Study  Report IMC -3G3-01).
Platelet-derived growth facto r/PDGFRα signaling has been implicated in the pathogenesis o f 
multiple cancers, including sarco ma, prostate cancer, breast cancer, ov arian cancer, and others.  
In malignant disease, the PDGF/PDGFRα axis promotes tumor growth and proliferat ion through 
both autocrine and paracrine mechanisms.  Platelet -derived growth factor receptor alpha can be 
expressed in both the tumor and stromal mic roenvironm ent.  Furthermore, studies have shown 
that PDGF/PDGFRα signaling affects tumor vasculature through paracrine mediat ion of vascular 
endothelial growth factor production (Shah et al. 2010).
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 19
LY3012207More informat ion on the known and ex pected benefits, risks, and reasonably  anticipated adverse 
events (AEs) of olaratumab may be found in the Investigator’s Brochure (IB).  Informat ion on 
AEs expected to be related to the invest igational product (IP) may be found in Sect ion 7 
(Development Core Safet y Inform ation[DCSI] ) of the IB.  Information on serious adverse 
events (SAEs) expected in the study  popul ation independent of drug exposure and that will be 
assessed by  [CONTACT_240209], periodically during the course of the study , may  be found 
in Section 6 (Effects in Humans) of the IB.
More informat ion about the known and expected benefits and risks of doxorubicin hydrochloride 
can be found in the approved doxorubicin package insert.
5.4. Rationale for Selection of Dose
The current olaratumab dose -select ion strategy  for thi s study  is based on the integrated safet y, 
efficacy , and PK data for ol aratum ab across previo us Phase 1 and Phase 2 studies.  
In 2Phase 1 dose -escalation trials (Studies I5B -IE-JGDC and I5B -IE-JGDF) and in the 2 Phase 
2 monotherapy  studi es (Studies I5B-IE-JGDE and I5B-IE-JGDH ), single -agent ol aratumab has 
consistent ly been well tol erated, wi th no dose -limiting toxicit ies observed up to a dose of 20 
mg/kg administered every 2 week s and up to a dose of 15 mg/kg administered on Days 1 and 8 
of a 21 -day cycle .  
When used in co mbination wit h liposo mal doxorubicin in Study  I5B-IE-
JGDA (olaratum ab dose of 20 mg/kg every  2 weeks), and wi th paclitaxel plus carboplat in in 
Study  I5B-IE-JGDB (olaratumab dose of 15 mg/kg Day s 1 and 8 every  3 weeks), a higher rate of 
toxicities such as neutropenia and infect ions was observed versus the comparator agents .  In 
Study  JGDG, an increase in neutropenia and mucosit is, but not in neutropenic sepsis or febrile 
neutropeni a, was observed for olaratumab plus doxorubicin co mpared wit h single- agent 
doxorubi cin.  Overall, these toxicit ies are consistent with the toxicit y profile of the combinat ion 
agents used, and are considere d monitorable and acceptable for the patient populat ions studied.
Based on an exposure -response analysis o f data from Study  JGDG, an ol aratum ab loading dose 
of 20 m g/kg on Day  1 and Day  8 of Cycle 1 was incorp orated into Study  I5B-MC-JGDJ (JGDJ), 
an ongoing randomized Phase [ADDRESS_1153959] of an init ial cycle of olaratumab mo notherapy  (Cycle 1) administered 
on Day  1 and Day  8 of a 21 -day cycle using a dose of 20 mg/kg.  This dose is consistent with the 
loading dose used in Study  JGDJ ,and is ant icipated to prov ide olaratum ab concentrati ons 
optimal for testing o laratumab tumor and CTC biomarker effects during Cycle 1.   
Because t he patient populat ion for Study  JGDM consists of pat ients who have potentially 
resectable STS , early tumor reducti on is an important the rapeutic goal.  Therefore, in Cycle 2, 
patients willreceive addit ional 20 mg/kg doses of olaratumab on Day  1 and Day 8, in 
combinat ion with 75 m g/m2doxorubi cinon Day 1 of a 21 -day cycle (totaling 2 cycles of 
olaratum ab at a 20 m g/kg dose : 1as monotherapy and 1in co mbination wit h doxorubicin).   This 
dosing schedule is intended to maximize the number of patients reaching potentially therapeut ic 
I5B-MC-JGDM (c)Phase [ADDRESS_1153960] 6 weeks, which is potenti ally important in this patient populat ion. 
Pharmacokinet ic model simulat ions indicate that this proposed dosing regimen may result in 
exposures slightly (approximately 15%) above previously studied steady -state serum  levels o f 
olaratum ab.  However, given the previously  acceptable toxicity profi le of o laratumab in 
combinat ion with doxorubi cinin Study  JGDG , it is not anticipated that this will result in any 
additional safety  risk to the pati ents enrolled in this study .
From  Cycle 3through Cycle 7 ,patients will receive olaratumab at a dose of 15 mg/kg on Day  1 
and Day 8, in combinat ion withdoxorubi cin 75 mg/m 2on Day  1of a 21 -day cycle, the same 
doses studied in Study JGDG .
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 21
LY30122076.Investigational Plan
6.1. Study Population
The durati on of  the screening period is 14 day s for the m ajority of procedures ( Attachment 1); 
certain noted procedures may be performed wit hin 28 day s of enrollment. Individuals who do 
not m eet the cri teria for parti cipat ion in this study  within the 28 -day screening peri od (screen 
failure) may  be re-screened .  Note that repeating laboratory  tests during the 28-day screening 
period does not const itute re -
screening.  Screening laboratory tests m ay not be repeated m ore 
than once to meet eli gibili tyduring the 28-day screening period .  
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also know n as 
protocol  waivers or exempt ions, are not permitted
.
6.1.1. Inclusion Criteria
Patients m ay be included in the study  if they  meet all  of the f ollowing cri teria during screening 
prior to first dose of study  drug.
[1] Have a histologically  confirmed di agnosis of STS for which olaratumab and 
doxorubi cin woul d be appropri ate therapy .  Pati ents wi th a diagnosis of 
Grade 1 liposarcoma are eligible if there is histological or radiographic 
evidence of evo lution to m ore aggressive disease .  Pati ents wi th Kaposi’s 
sarcoma and gastrointestinal stromal tumors (GIST) will be excluded .  
Patients must have potenti ally resectable disease (as assessed by  [CONTACT_229197]) and have a primary  tumor lesion deemed amenable to serial 
biopsy.
[2] Have consented to undergo mandatory  serial  peripheral  whole blood and 
tumor tissue sampling for pathology  review and translat ional research.  Refer 
to Section s8.2.3.1 and [IP_ADDRESS] for details of biopsy and who le blood sam ple 
collect ion.  
[3] H ave signed an informed consent form (ICF) and authori zation for release of 
healt h informat ion for research prior to any  study -specific procedures being 
perform ed.
[4] A re age 18 years at time of consent.
[
5] H ave measurable or nonmeasurable but evaluable disease as defined by [CONTACT_240210] (RECIST v1.1, Ei senhauer et 
al. 2009). Tumors wi thin a previously irradiated field will be designated as 
“nontarget” lesio ns unless progression is documented or a biopsy is obtained 
toconfirm persistence at least 90 days fo llowing com pletion of radiotherapy .
[
6] H ave a performance status (PS) of 0 to 1 on the Eastern Cooperative 
Onco logy Group (ECOG) scale (Oken et al. 1982).  
 Attachment 6 provides the 
ECOG PS scale.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 22
LY3012207[7] H ave had 2prior sy stemic cy totoxi c therapi [INVESTIGATOR_831411] .  
All previous anticancer treatments must have been co mpleted 
≥3weeks (21 days) pri or to enrollment .
[8] H ave had resolution of AEs and of all  clinically significant toxic effects of 
prior locoregi onal therapy , surgery , radi otherapy , or sy stemic ant icancer 
therapy  to Grade ≤1, by  [CONTACT_240211](NCI) -Common 
Termino logy Cri teria for Adverse Events (CTCAE) Version 4.0.
[9] Have adequate hematologic, organ, coagulat ion, and cardiac funct ion within 
2weeks (14 days) prior to enrollment:
• Absolute neutrophil count (ANC) ≥1.5 x 109/L.  Granulocyte co lony
-
stimulat ing factor (G -CSF) cannot be administered within 2 weeks 
(14days) prior to enrollment .
• Platelet coun t ≥100 x 109/L.
• Hem oglobin ≥9.0 g/dL .  No transfusio nsare allowed wi thin 2 weeks 
(14days) prior to enrollment .
• C reatinine clearance ≥45 mL/min (refer to Attachment 7 for the 
Cockcroft -Gaul t formula).
• Proteinuria ≤1000 m g in 24 hours (if r outine urinalysis indicates 
≥2+proteinuria).
• Total  bilirubin below upper limit of normal (ULN) (except for patients 
with Gilbert’s Syndro me, who must have a total bilirubin <3 mg/dL) .
• Alanine aminotransferase (ALT) /aspartate aminotransferase (AST) 
≤3.0 × ULN; if the liver has tumor invo lvement, AST and ALT ≤5.0 × 
ULN are acceptable.
An adequate coagulat ion function as defined by [CONTACT_240212]≤1.[ADDRESS_1153961] or prothrombin t ime ≤1.[ADDRESS_1153962] astintime
≤1.[ADDRESS_1153963] no hi story  of active bleeding 
(defined as within [ADDRESS_1153964] dose of study  drug) or pathological 
condi tion that carries a high risk of bleeding ( for example , tum or 
involving m ajor vessels or known esophageal varices) .
[10] Ha veleft ventri cular ejection fraction (LVEF) ≥50% assessed within 28 days 
prior to enrollment .
[
11]Females of child -bearing potential must have a negative serum or urine 
pregnancy test within 7 days prior to enrollment.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 23
LY3012207• Except ions:  females not of child- bearing potential due to surgical 
sterilizat ion (at l east 6 weeks fo llowing surgical bilateral oophorectomy 
with or wi thout hy sterectomy or tubal ligat ion) confirmed by [CONTACT_831432] m enopause.
A “postmenopausal woman” is a woman meet ing eit her of the fo llowing 
criteria:
•spontaneous amenorrhea for at least 12 months, not induced by a medical 
condi tion such as anorexia nervosa and not taking medicat ions during the 
amenorrhea that induced the amenorrhea (for example, oral 
contraceptives, hormones, gonadotropin releasing h ormone, ant iestrogens, 
select ive estrogen receptor modulators, or chemotherapy)
• spontaneous amenorrhea for 6 to 12 months and a fo llicle -stimulat ing 
horm one l evel >40 m IU/mL
[12] Females of child -bearing potential must agree to use highly effect ive 
contr aceptive precaut ions and m en must agree to use effect ive contraceptive 
methods (for example, condom  with spermicide) during the trial and up to [ADDRESS_1153965] ive method of birth 
control  is defined as one th at resul ts in a l ow failure rate (that is, <1% per y ear) 
when used consistent ly and correctly, such as implants, injectables, combined 
oral contraceptives, some intrauterine contraceptive devices, a vasectomized 
partner ,or sexual abstinence that is in line with the preferred and usual lifest yle 
of the subject ( periodic abst inence [ for example , calendar, ovul ation, 
symptothermal, post -ovulation methods], decl aration of abst inence for the 
durati on of  a trial , and wi thdrawal  are not acceptable methods of cont racepti on)
.
[13]Have, in the opi[INVESTIGATOR_3078] n of the invest igator, a life expectancy o f at least 3 m onths.
6.1.2. Exclusion Criteria
Potenti al study  patients m ay not be included in the study  if any of the fo llowing apply during 
screening.   
[14]Have a diagnosis of GIST or Kaposi sarcoma .
[
15]Have active central nervous system (CNS) or leptomeningeal metastasis (brain 
metastasis) at th e time of enro llment .  Patients with a history  of a CNS 
metastasis previously treated with curative intent (for example, stereotactic 
radiation or surgery ) that have not progressed on follow- up imaging, have been 
asymptomat ic for at least 60 days ,and are not receiving systemic corticosteroids 
and or/anticonvulsants are eligible. Patients wi th signs or symptoms of 
neuro logical com promise shoul d have appropri ate radi ographic imaging 
perform ed before enrollment to rule out brain metastasis.
[16]Have received pri or treatm ent wi th doxorubi cin, epi [INVESTIGATOR_14962], i darubicin, and/or 
other anthracy clines or anthracenedio nes; has received treatment with 
olaratum ab or has participated in a prior olaratumab trial.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 24
LY3012207[17] Have a history  of another primary  cancer, wi th the exception of a) curatively 
treated non -melanomatous skin cancer; b) curatively  treated cervi cal carcino ma 
in situ; c) other primary  non-hematol ogic malignancies or solid tumor treated 
with curative intent; no known active di sease ;and no treatment admi nistered 
during the last 3 y ears pri or to enrollment .
[
18]Have unstable angina pectoris, angioplast y, cardiac stenting, or my ocardial  
infarction wit hin 6 months of enrollment. 
[
19]Have a Bazett’s corrected QT interval of >450 ms ecfor males and > 470 m sec
for females on screening ECG utilizing Bazett’s correction. For bundle branch 
block pat ients, have a QTcF interval o f >450 m secfor males and >470 m s for 
females on screening ECG utilizing Fridericia’s correction
.
[20] Are females who are pregnan t or breastfeeding.
[
21]Are enrolled in, or discont inued study  treatm ent from,another trial invo lving an 
investigat ional agent or use of non -approved drug or device within 28 days o f 
being enrolled/rando mized in this trial, or concurrent enrollment in an y other 
type of medical research judged scientifically or medically incompat ible with 
this trial.  Pati ents parti cipat ing in surveys or observat ional studi es are eligible 
to parti cipate in thi s study .
[
22]Have serious pre-exist ing medical condi tions that ,in the opi[INVESTIGATOR_3078] n of the 
investigator ,would exclude the patient as a candidate for this study .
[
23]Have a known allergy to any  of the treatm ent components including a history  of 
allergic reactions attributed to compounds of chemical or bio logical co mposit i
on 
similar to olaratumab .
6.2. Summary of Study Design
Study  JGDM is an open -label, single -arm, mul ticenter, m ulticountry  Phase 1b study to 
enumerate who le blood CTCs and to characterize PDGFR and PDGFR and canonical ligands
(PDGF -A, B, C and D)expressio n changes pre -and post -olaratum ab m onotherapy  in tumor 
tissue inpatients with potenti ally resectable STS.
Patients are to be treated wi th 20 m g/kg of ol aratumab on Day 1and D ay 8ofCycle 1,followed 
by [CONTACT_8622] 6cycles (C ycle 2
– Cycle 7) of combinat ion therapy wit h olaratum ab plus doxorubi cin.  
For C ycle 2, olaratum ab is to be dosed at 20 m g/kg on D ay 1 and D ay 8 and doxorubicin is to be 
dosed at 75 mg/m 2on D ay 1.  For Cycle 3
– Cycle 7, olaratumab is to be dosed at 15 mg/kg on
Day 1 and D ay 8 and doxorubicin is to be dosed at 75mg/m2on D ay 1.  Each cycle of treatment 
is defined as an interval o f [ADDRESS_1153966] cy cle of combinat ion therapy (Cycle 2), the use of dexrazoxane (in a 10:1 
ratio vs. doxorubicin dose) to mit igate cardi otoxi city during treatm ent wi th doxorubi cin is 
allowed at the invest igator’s discret ion and is recommended for all pat ients receiving 5 or more 
cycles of doxorubi cin.
I5B-MC-JGDM (c)Phase [ADDRESS_1153967] tissue biopsy (or 
tissue from a posttherapy  surgical  resecti on specimen )maybe perform edat the end of the 
patient’s study  treatm ent.  If clinically  feasible, the tissue biopsies should be taken from the same 
primary  tumorlesion.  If the patient has an addit ional surgical resect ion, tissue from  this 
procedure is requested.  Refer to Section
 [IP_ADDRESS] for details on tissue biopsies. 
Who le blood sam ples for CTC analyses are to be collected predose at Cycle 1 Day  1 (C1D1 ), at 
Cycle 1 Day  8 (C1D8), at Cycle 2 Day  1 (C2D1 ), at Cy cle 2 Day  8 (C2D8), at Cycle 3 Day 1 
(C3D1 ), and at the end of the patient’s study  treatment or at the time of surgical resection .  Refer 
to Section [IP_ADDRESS] for details on blood samples.
After 1 cy cle of m onotherapy , patients will receive combination therapy  for up to 6cycles or 
until evidence of progressive disease (PD), unacceptable toxicit y, surgical resect ion, death, or 
other withdrawal criteria are met.  Patients who discontinue study  treatm ent for reasons other 
than progression or surgical resect ion will be fo llowed every  6 weeks (±7 day s) until PD.
Refer to Attachment 1 for the Study  Schedule.
Figure JGDM. 1illustrates the study  design.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 26
LY3012207Abbreviati ons:  C1D1 = Cycle 1 Day 1; C2D1 = Cycle 2 Day 1; C3D1 = Cycle 3 Day 
1; CTC = circulating tumor cell; D = day (s); ECOG PS = Eastern Cooperative 
Oncology Group performance status; STS = soft tissue sarcoma, tx = treatment.
aThe p re-and post -
olaratumab monotherapy tissue biops iesand the whole blood 
sample collections pre -dose at C1D1 , C1D8, C2D1 , and C2D8 for CTC analyses are 
mandato ry. The p re-olaratumab monotherapy biopsy is to be collected within the 
screening period .  The p ost-olaratuma b monotherapy biopsy is to be collected after 
completion of Cycle 1and prio r to initiation of Cycle [ADDRESS_1153968] tumor tissue biopsy is to be collected at the end of the patient’s 
study treatment or when the patient undergoes a surgical resection through which a 
posttherapy  tissue specimen can be collected.  If clinically feasible, the biopsies should 
be taken from the same primary tum or lesion.   Additionally, a whole blood sample for 
CTC analysis is to be collected at C3D1 and at the end of the patient’s study treatment 
or at the time of surgical resection. 
cSeetext in Section 6.2,Summary of Study Design.
Note :  Each cycle of treatment is defined as an interval of 21 days.
Figure JGDM. 1. Illustration of study design.
Terms used to describe the periods during the study  are defined bel ow:
Baseline:   begins when the ICF is signed (study  entry ) and ends at the first study  
treatm ent (or at di scont inuat ion, if no treatment is given).
Study Period:   begins at the first study treatment and ends at study completion.
oStudy Treatment Period:   begins at the first study treatment and ends when the 
patient and the invest igator agree that the patient will no longer continue study  

I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 27
LY3012207treatm ent.  The date of this agreement is to be reported on the electronic case 
report form (eCRF) as the Date of Discont inuat ion fro m study  treatm ent.
Olaratumab Monotherapy Treatment Period: begins at the first 
administration of olaratumab 20 mg/kg on Day 1of Cyc le 1 and ends on 
Day 21 of  Cycle 1.
Combination Olaratumab plus Doxorub icin Therapy Treatment 
Period :  begins after the post Cy cle [ADDRESS_1153969] administration o f olaratum ab 20 m g/kg and doxorubicin 75 mg/m2
on Day  1 of Cycle 2 , followed by [CONTACT_43602] o laratumab 
20mg/kg on Day 8 of Cycle 2.  Thi s treatment period continues from 
Cycle 3 through Cycle 7 with the administrati on of olaratum ab at a dose of 
15 m g/kg on Days 1 and 8 and doxorubicin 75 mg/m2on Day  [ADDRESS_1153970]-discontinuation Follow -Up:  
begins the day  after the pati ent and the 
investigator agree that the patient will no longer cont inue study  treatm ent.
Short -term follow -up: begins the d ay after the pati ent and the 
investigator agree that the patient will no longer cont inue study  treatm ent 
and lasts approximately  30 days (±7 days).  The short -term follow-up visit 
occurs at or near the end of the short -term follow -up peri od (±7 days).
Follow-up for safet y -Patients who undergo surgical resect ion will 
be followed for safet y for approximately 30 days (±7 days) after 
surgery .
Long -term follow- up: begins the day  after short -term follow-up is 
completed.
Follow-up for progression -Patients who discont inue study  
treatm ent,or have completed6 cycles of combinatio n therapy ,and 
have not progressed and have not init iated a new systemic 
treatm ent for thei r disease will be assessed for progressio nby 
[CONTACT_334863]  6 weeks ( <7 day s) unt il PD .  Patients who 
have had surgical resect ion will not be fo llowed for subsequent 
progression by [CONTACT_20521].
6.2.1. Study Completion and End of Trial
The study  will be considered com plete after all patients have progressed or undergo nesurgical 
resection and com pleted the follow-up peri od. The end of trial occurs after study  com pletion and 
after the l ast pati ent has discont inued study  treatment and completed the 30- day follow-up 
period. 
6.3. Discontinuation s
The reason for discontinuat ion and the date of di scontinuat ion will be collected for all patients.  
The date of discontinuati on from study  treatm ent for any of the reasons specified in Sect ion6.3.2
I5B-MC-JGDM (c)Phase [ADDRESS_1153971] fo llow-up procedures 
perform ed as shown in the Study  Schedule ( Attachment 1 ).
If a patient withdraws informed consent, he or she must not be contact[CONTACT_133392] n and consent.  Lilly may cont inue to use pr eviously co llected 
medical research data prior to the withdrawal consistent with the original authorizat ion.
6.3.1. Discontinuation of Patients Inadvertently Enrolled
The cri teria for enrollment m ust be fo llowed explici tly. If the invest igator si te identifies a patient 
who did not meet enrollment criteria and who was inadvertent ly enro lled, the sponsor must be 
notified.   If the sponsor ident ifies a pat ient who did not meet enrollment criteria and who was 
inadvertent ly enro lled, the invest igator si te will  be notified. A discussio n must occur between 
the sponsor clinical research physician ( CRP )and the invest igator to determine whether the 
patient may  cont inue in the study , with or wi thout IP.  Inadvertently enro lled patients may be 
maintaine d in the study  and on IPwhen the Lilly CRP agree swith the invest igator that it is 
medically appropriate for that patient. The patient may not continue in the study  with or wi thout 
IPif the Lilly  CRP does not agree with the invest igator’s determinat ion that 
it is m edically 
appropriate for the patient to con tinue. The invest igator must obtain documented approval fro m 
the Lilly CRP to allow the inadvertent ly enro lled patient to continue in the study with or without 
IP.
6.3.2. Discontinuation of Patients from Stu dyor Study Drug
The date of and the reason for discontinuation from study  treatm ent will be collected for all 
patients; the date of discont inuat ion from study treatment (for any  of the reasons listed below) is 
to be reported on the eCRF.  Patients who di scont inue study  treatm ent will  have fo llow-up 
procedures performed as shown in the Study  Schedul e (Attachment 1 ).
Inaddition, pati ents will  be discont inued fro m the study  drug and/or from the study  in the 
following circumstances:
enrollment in any other clinical trial invo lving an IPor enrollment in any 
other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study
investigator /physician decisio n
othe invest igator/physician decides that the patient should be discontinued from the 
study  or study drug(s)
othe pati ent, f or any  reason, requi res treatm ent wi th another therapeuti c agent that 
has been demonstrated to be effect ive for treatm ent of the study  indicat ion, 
discontinuat ion from the study  drug(s) occurs prior to introduction of the other 
agent
patient deci sion
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 29
LY3012207othe pati ent or the pati ent’s designee (for example, parents or legal g uardian) 
requests to be discont inued fro m the study  or study drug
sponsor decisio n
oLilly stops the study  or stops the patient’s participation in the study  for medical, 
safet y, regul atory , or other reasons consistent with applicable laws, regulat ions, 
and GCP
evidence of PD
unacceptable toxicit y
pregnancy
surgi cal resect ion
significant noncom pliance wi th study  procedures and/or treatment .
6.3.3. Patients Lost to Follow -Up
A pat ient will be considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  [CONTACT_4145].  Study  site personnel are expected to m ake 
diligent attempts to contact [CONTACT_57986] a scheduled visit ,or with who m the site 
is othe rwise unable to follow -up.
6.3.4. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly , the invest igator, or the ethical review board 
(ERB) of the study  site judges discont inuat ion of study  site parti cipat ion necessary  for any 
scientific, medical, safet y, regul atory , ethi cal, or other reason s consistent with applicable laws, 
regul ations, and GCP .
6.3.5. Discontinuation of the Study
The study  will be di scontinued if Lilly , while considering the ri ghts, safet y, and well -being o f the 
patient(s), judges discont inuat ion of the study necessary  for any scient ific, medical, safet y, 
regul atory , ethical , or other reasons consistent with applicable laws, regulat ions, and GCP .
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 30
LY30122077.Treatment
7.1. Materials and Supplie s
7.1.1. Packaging and Labelling
Olaratum ab will be provided by  [CONTACT_11007] .  
Olaratum abwill be supplied as a sterile preservat ive-free solut ion for IV infusio n in single -use 
vials containing 500 mg/50 mL of olaratum ab(10mg/mL).  
Olaratum abis formulated in 10 mM histidine, 100 mM glycine, 50 mM sodi um chloride, 75 mM 
mannito l, and 0.02% polysorbate- 20, pH 5.5.  All excipi[INVESTIGATOR_831412].
Where co mmercially available, doxorubicin hydrochloride will be purchased by [CONTACT_30107].  In the 
event that there are regional restrict ions or supply  limitations, doxorubicin may be provided to 
the sites by  [CONTACT_11007] .
Where co mmercially available, dexrazoxane will be purchased by [CONTACT_30107].  In the event that 
there are regional restrict ions or supply limitat ions, dexrazoxane may  be provi ded to the si tes by 
[CONTACT_11007].
Clinical study  materials will be l abeled according to th e country ’s regul atory  requi rements.
7.1.2. Olaratumab
Olaratum ab Drug Product:  The drug product must be stored under refrigerat ion at 2°C -8°C 
(36°F -46°F) wi th protecti on from direct light.  Do not freeze and/or shake olaratumab drug 
product.   Stabilit y studies have demonstrated that the drug product can withstand transient 
excursio n to room  temperature wi thout adverse effect; however, storage at this temperature is not 
recommended.
Please refer to the Pharmacy  Manual for information on prepar ing the olaratumab dosing 
solution for infusio n.
CAUTION:  Infusion -related reacti ons may  occur during or following olaratumab administration 
(see Section [IP_ADDRESS].1.1 for a definit ion of Grade 3 and 4 IRRs).  During the administration of 
olaratum ab, pati ents shoul d be in an area with resuscitation equipment and treatments necessary 
for advanced life support and cardiopulmo nary resusci tation, such as b ronchodilators, 
vasopressor agents ( for example , epi[INVESTIGATOR_238]), oxygen, glucocorticoids, antihistamines, and IV 
fluids.  A [ADDRESS_1153972] ituted observat ion peri od m ay be suspended after 2 cycles 
if the pat ient shows no further signs or symptoms of an IRR. 
I5B-MC-JGDM (c)Phase [ADDRESS_1153973] igators should consult the approved doxorubicin hydrochloride package insert for complete 
prescribing information (including warnings, precautions, contraindicat ions, adverse react ions, 
and dose m odificat ions) and fo llow inst itutional procedures for the administration of 
doxorubi cin.  If a pat ient should have an IRR to doxorubicin , the investi gator shoul d follow the 
manufacturer’s recommendat ions and clinical guidelines in the management of the patient .  
Doxorubi cin 75 mg/m 2is administered IV.  The dose of doxorubicin should be reconst ituted i n 
100mL of normal saline.  Administer doxorubicin as an IV inject ion or as an infusio n in less 
than [ADDRESS_1153974] be reconstituted prior to infusio n.  The reconstituted solut ion is stable for 
7days at room  temperature and under normal room light and 15 day s under refri gerat ion (2ºC -
8ºC[36ºF -46ºF] ).  It should be protected from exposure to sunlight.
Parenteral  drug products should be inspected visually  for parti culate matter and disco loration 
prior to administration, whenever solut ion and container permit.
Clinical study  materials will be l abeled acc ording to the country ’s regul atory  requi rements. 
See Secti on 7. 5.1.[ADDRESS_1153975] igator or designee is responsible for:
explaining the correct use of the drugs and planned durati on of  each individual’s 
treatm ent to the patient/study  site personnel/legal representative
verifying that instructions are fo llowed properly 
maintaining accurate records of study  drug dispensati on, and co llection, and 
returning or destroyi ng all unused m edicat ion to Lilly or its designee at the end of 
the study
Patients will  be instructed to contact [CONTACT_240220] a com plaint 
or probl em with the study  drug so that the situation can be assessed.
7.2.1. Treatments Administered
Table JGDM. 1shows the treatment regimens to be administered in this study .
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 32
LY3012207Table JGDM. 1. Treatment Regimens
Treatment Cycle
Length
(Days)Study Drug Dose Timing Route 
Monotherapy 
Cycle 121 Olaratumaba20 mg/kg approximately 1 hour 
infusion D1, D8 IV
1-hour ( +5 minutes) 
Observation Periodb
Combination Therapy
Cycle 221 Olaratumaba20 mg/kg approximately 1 hour 
infusion D1, D8 IV
1-hour ( +5 minutes) 
Observation Periodb
followed by
[CONTACT_240219]75 mg/m2IV injection on D1 IV
Combination Therapy
Cycle 3 –Cycle 721 Olaratumaba15mg/kg approximately 1 hour 
infusion D1, D8 IV
Doxorubicinc75 mg/m2IV injection on D1 IV
Abbreviations:  D =day; eCRF = electronic case report form; IRR = infusion -related reaction; IV = intravenous; 
PO= orally.
aPremedicate all patients with the following (or equivalent) medications :  a histamine H1 antagonist (for  example , 
diphenhydramine) and dexamethasone intravenously 30 –[ADDRESS_1153976] (
for example , 
diphenhydramine) intravenously 30-60 minutes prior to each dose of olaratumab.  Additional premedication may 
be provided at the investigator’s discretion.  Premedication must be provided in the setting of a prior Grad
e 1-2 
IRR, as detailed in Section 7.2.2 and Section [IP_ADDRESS].1.[ADDRESS_1153977] be adequately 
documen ted in the eCRF.
bA 1-hour (+5 minutes) Observation Period is required after the administration of the initial [ADDRESS_1153978] vital signs 3 times:  1) within 15 minutes (+5 minutes) prior 
to olaratumab infusion, 2) within 1 hour (+5 minutes) after completion of the olaratumab infusion, and 3) within 
1 hour (+5 minutes) after completion of the doxorubicin infusion.  If no evidence of an IRR manifests during the 
initial 2 cycles of olaratumab, then no observat ion period is required for subsequent treatment cycles.  In the 
event an IRR occurs thereafter, then the 1 -hour O bservation Period should be reinstituted ;see Section 7.1.2 .  
Thereafter (Cycles 3+), obtain vital signs 2 times:  1) within 15 minutes (+5 minutes) prior to olaratumab 
infusion and 2) within 1 hour (+5 minutes) after completion of the doxorubicin inf usion.
cAdminister doxorubicin according to institutional guidelines and/or clinical practice as an IV injection or as an 
infusion within 60 minutes.  Decrease the rate of doxorubicin administration if erythematous streaking along the 
vein proximal to the site of infusion or facial flushing occur s.  Infusion or injection start and end times will need 
to be recorded.  Starting with Cycle 2, dexrazoxane may be administered at a 10:1 ratio 
(dexrazoxane:doxorubicin) at the investigator’s discretion according t o instructions provided in the pharmacy 
manual for this study, beginning within [ADDRESS_1153979] cy cle of 
olaratum ab treat ment.  Therefore, premedicate all patients with the following (or equivalent) 
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 33
LY3012207medicat ions:  a histamine H1 antagonist (for example , diphenhydramine) and dexamethasone 
intravenously 30–[ADDRESS_1153980] (for example , 
diphenhydramine) intravenously 30-[ADDRESS_1153981] ion 
[IP_ADDRESS].1.[ADDRESS_1153982] be done 
after com pletion of the olaratum ab infusi on, not before the ol aratum ab infusi on. This 
prem edicat ion may be administered immediately following the end of the observation period (if 
applicable) or after complet ion of the olaratumab infusio n.
Starti ng wit h Cycle 2, dexrazoxane may be administered IV at a 10:1 ratio 
(dexrazoxane:doxorubicin) at the investigator’s discretion according to instructions provided in 
the pharmacy manual for this study , beginning no later than 30 minutes prior to each doxorubicin 
infusio n for the prevent ion of cardiotoxicit y.It is recommended that all pat ients receiving 5 or 
more cycles of doxorubicin receive dexrazoxane.
7.2.3. Dose Modifications
[IP_ADDRESS]. Dose Delays, Modifications, and Discontinuations 
After treatment has been init iated, in order to start the next cycle ,the following cri teria m ust be
fulfilled:
ANC ≥1.0 × 103/L (1000/ L; ≥1.0 × 109/L)
Note that in order to administer single- agent o laratumab on Day 8, ANC must 
be 750/L; 0.75 × 109/L.  If the ANC is 750/L, the Day  8 administrati on 
of olaratum ab may  be delayed for a m aximum  of 7 day s.  If the ANC level has 
not increased to 750/L within 7 days, then the Day 8 olaratumab dose in 
that cy cle shoul d be skipped and dosing resumed on Day  1 of the f ollowing 
cycle if cri teria f or dosing are met.  If all dosing criteria are met, a delay  or 
omissio n of the Day  8 olaratum ab dose shoul d not resul t in a delay  of the 
Day 1 olaratum ab dose of t he fo llowing cycle. 
Platelets ≥100 × 103/L (100,000/ L; ≥100 × 109/L)
Hem oglobin ≥
8g/dL
Creatinine clearance ≥45 mL/min (refer to Attachment 7 for the 
Cockcroft -Gaul t formula)
Proteinuria ≤1000 m g in 24 hours (if routi ne urinalysis indicates 
≥2+proteinuria) (to be performed every other cy cle)
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 34
LY3012207Total  bilirubin below ULN
AST and ALT ≤3.[ADDRESS_1153983], or ≤[ADDRESS_1153984] if the transaminase elevat ion is due 
to liver metastases
Olaratum ab-related AEs that ar e NCI-CTCAE Versi on 4.0 Grade <2 or 
equivalen t severit y to baseline
Delays:
In general, dose delays of 1 study  drug (ol aratum ab or doxorubi cin) due to toxi city guidances 
outlined in Sect ions [IP_ADDRESS].1 and [IP_ADDRESS].2 will not necessitate delays of the other study drug.
Treatment may be delayed f or up to 21 days (1 equivalent cy cle) to allow a patient sufficient 
time for recovery  from study  drug -related toxi city.  If a pati ent does not recover from the toxicit y 
within 42 days (2 equivalent cy cles) fro m Day [ADDRESS_1153985] be discont inued fro m study  therapy .
Any procedure or sam ple collection whose timing is related to o laratumab dosing is to be 
completed acco rding to when the o laratumab dose was actually administered, not when that d ose 
was expected to occur .  Samples whose adjusted timing would fall outsi de of the treatm ent cy cle 
durati on due to dose delay  may be omitted.
Dose Modificat ions:
Any pat ient who requires a dose reduction will continue to receive the reduced dose for the 
remainder of the study .  Any  patient who has had [ADDRESS_1153986] be discont inued fro m study  drug.
In the event of an alteration in o laratumab dose due to an olaratumab -related tox icity, 
doxorubi cin need not be altered, and the planned doxorubicin schedule should be maintained.
Similarly, olaratumab therapy  need not be al tered for doxorubi cin-related toxi city.  An al terati on 
in doxorubicin dose will always necessitate a correspondin g change to dexrazoxane, if 
administered, in order to maintain a dosage ratio of 10:1 (dexrazoxane:doxorubicin).
Discontinuati ons:
In general, discont inuation o f olaratum ab will not necessitate discontinuat ion of doxorubicin .  In 
the event of discont inuat ion of olaratumab therapy due to an olaratumab- related toxi city or 
Grade 3 or 4IRR, doxorubicin need not be altered, and the planned doxorubicin schedule may be 
maintained at the discret ion of the investigator.  Discontinuation o f doxorubi cin will necessi tate 
discontinuat ion of o laratumab.
Any changes in treatments being added to or removed fro m patient care will be recorded on the 
eCRF.
The fo llowing inform ation (in this sect ion and the fo llowing subsect ions) pertains to dose 
modificati ons and delays for and management of AEs of concern, which may  or m ay not be 
associ ated wi th olaratum ab therapy , including the following:
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 35
LY3012207IRR (see Section [IP_ADDRESS].1.1 )
Hem atologic toxici ty (see Sect ion [IP_ADDRESS].1.2 )
Nonhematologic toxicit y (see Sect ion [IP_ADDRESS].1.3 )
The fo llowing inform ation (in this sect ion and the fo llowing subsect ions) pertains to dose 
modificati ons and del ays for and management of AEs of concern, which may  or m ay not be 
associ ated wi th doxorubi cin therapy, including the fo llowing:
Hem atologic toxici ty (see Sect ion [IP_ADDRESS].2.1 )
Cardi ovascular toxi city (see Secti on [IP_ADDRESS].2.2 )
Hepati c impai rment (see Secti on [IP_ADDRESS].2.3 )
Nonhematologic toxicit y (Sect ion7.[IP_ADDRESS].4 )
[IP_ADDRESS].1. Olaratumab
[IP_ADDRESS].1.1. Infusion -Related Reaction s
As wi th other therapeuti c protein products , hypersensit ivity react ions may occur during or 
following o laratumab administration.
For the init ial [ADDRESS_1153987] 1 hour after the end of the infusion (see Table JGDM. 1) in an area where 
emergency medical resuscitat ion equipment and other agents ( such as epi[INVESTIGATOR_831413]) are available.   
Ifno evidence of an IRR manifests during the init ial 
2cycles o f olaratum ab, then no observat ion period is requi red for subsequent treatm ent cy cles.  
In the event an IRR occurs thereafter, then the 1- hour observation period should be reinst ituted
(see Section 7.1.2 ).  
Olaratum ab IRRs will be defined according to the NCI -CTCAE Versi on 4.0 definit ion of IRRs.
Symptom s occurring during or following infusio n of investigational therapy  may also be defined 
according to AE terms such as allergic reaction, anaphylaxis, or cy tokine rel ease syndrom e 
(NCI -CTCAE Versi on 4.0 secti on “Immune system disorders”).  In the setting of symptoms 
occurring during or fo llowing infusio n of invest igational therapy, invest igators are encouraged to 
use the AE term “IRR ” and any addit ional term s (including those not listed here) that best 
describe the event.
For pati ents who experience a Grade 1 or 2 IRR, the infusio n should be stopped and the patient
treated wit
h the following (or equivalent) medicat ions:  a histamine H1 antagonist ( for example , 
diphenhydramine) and glucocorticoid ( for example , dexamethasone) IV, acetaminophen, and 
oxygen (as indicated), according to standard medical practices.  After recovery , the infusio n rate 
shoul d be decreased by 50% for the duration of the infusio n.  After a Grade 1 or 2 IRR, patients 
shoul d be prem edicated wi th the f ollowing (or equivalent) medications :  a histamine H1 
antagonist ( for example , diphenhydramine) a nd glucocortico id (for example , dexamethasone) IV, 
and acetaminophen, as appropriate, approximately 30 -60 minutes prior to all subsequent 
olaratum ab infusio ns.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 36
LY3012207A Grade 3 or 4 IRR will require immediate treatment, including the use of epi[INVESTIGATOR_238], 
bronchodi lators, and/or glucocortico ids for symptomat ic bronchospasm, IV fluids and/or 
pressors for hy potensi on, and immediate and permanent discont inuat ion of o laratumab with 
appropriate supportive care.
If a patient experiences an IRR to olaratumab, all attempts shoul d be m ade to obtain an 
anti-olaratum ab ant ibody  blood sam ple as cl ose to the onset of the event as possible, at the 
resol ution of the event, and 30 day s (±3 days) following the event.  In addit ion, these same 
samples may  be assessed for levels of olar atumab and for pharmacodynamic markers to provide 
inform ation on the nature of the IRR.  The procedure for sample collection and handling is 
described in a separate procedural manual.
Secti on 7.1.3 provides informat ion on doxorubicin and IRRs.
[IP_ADDRESS].1.2. Hematologic Toxicity
Table JGDM. 2summarizes the olaratumab dose modificat ions required in case of hematological 
toxicities.
Table JGDM. 2. General Guidelines for Olaratumab Dose Modification Due to 
Hem atologic Toxicity Deemed Related to Olaratumab
Toxicity Required Dose Modification
Neutropenia
  ANC Grade 1 -3 No dose modification required .
  ANC <500 cells/ L (Grade ≥4) No treatment administered; treatment cycle delayed .
  At retreatment:
  If  Grade ≥3 neutropenic fever/infection has 
occurredWithhold dose until ANC is 1000 cells/ L or higher; 
reduce dose to 12 mg/kg (15 mg/kg if toxicity occurs 
during Cycle 1 or Cycle 2).
  If Grade 4 neutropenia lasting longer than 1 week 
has occurredWithhold dose until ANC is 1000 cells/ L or higher; 
reduce dose to 12 mg/kg (15 mg/kg if toxicity occurs 
during Cycle 1 or Cycle 2).
  Grade 4 ANC without fever/infection Retreatment with olaratumab at full dose at investigator’s 
discretio n with recommended use of prophylactic G -CSFs .
  Second incidence of either:  
  1) Grade ≥3 neutropenic fever/infection
  2) Grade 4 neutropenia lasting longer than 1 weekSecond dose reduction to 10 mg/kg .
Thrombocytopenia
  Platelets <75,000 cells/ L (Grade 1) No treatment administered; treatment delayed until 
resolved to ≥100,000 cells/ L.
Anemia
  Hemoglobin <9 gm/dL (Grade 2) No treatment administered; treatment delayed until 
resolved to ≤Grade 1.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 37
LY3012207Abbreviations:  ANC = absolute neutrophil count; G -CSF = granulocyte colony -stimulating factor.
[IP_ADDRESS].1.3. Nonhematologic Toxicity
Specific guidelines for dose adjustments in pat ients who experience olaratumab IRRs may be 
found in Section [IP_ADDRESS].1.1 .
Table JGDM. 3provi des general guidelines for dose modificat ion for other nonhematologic 
toxicities related to ol aratumab.  If m ore than 2 toxicit y-related ol aratum ab dose reductions are 
requi red, treatm ent wi th this agent will be permanent ly discont inued.
Table JGDM. 3. General Guidelines for Olaratumab Dose Modification Due to 
Nonhematologic To xicityDeemed Related to Olaratumab
Reaction Grade Required Dose Modification
Grade 1 No dose modification is required.
Grade 2 At the investigator’s discretion, the patient may continue to receive olaratumab per protocol, 
provided that the event does not pose a serious health risk or is easily treated.
Grade [ADDRESS_1153988] be withheld until toxicity is Grade ≤1 or has returned to pretreatment baseline; then 
treatment may resume at a reduced dose of 12 mg/kg (15 mg/kg if the toxicity occurs during 
Cycle 1 or Cycle 2 ).  If toxicity recurs after therapy resumes, a second dose reduction (to 
10mg/kg) is permitted.
Grade [ADDRESS_1153989] be withheld until dose toxicity is ≤Grade 1 or has returned to baseline .  
Permanent discontinuation should be considered for any patient experiencing Grade 4 
nonhematological toxicity assessed as related to olaratumab .  However, if resumption of 
dosing is deemed appropriate by [CONTACT_1188], treatment may resume only after 
consultation with the Lilly study physician, with the dose reduced to 10 mg/kg (15 mg/kg if 
the toxicity occurs during Cycle 1 or Cycle 2 ).  If Grade 4 toxicity recurs after therapy 
resumes, olaratumab treatment will be discontinued.
[IP_ADDRESS].2. Doxorubicin
[IP_ADDRESS].2.1. Hematologic Toxicity
Doxorubi cin will not be administered after the init ial dose if the patient’s ANC is <1000 cells/ L 
or if the platelet coun t is <100,000 cells/ L.  When necessary , the next treatm ent cycle should be 
delayed unt il the ANC is ≥1000 cells/ L and the platelet count is ≥100,000 cells/ L and 
nonhematologic toxicit ies have resolved.  For patients who experience ≥Grade [ADDRESS_1153990] ing more than 1 we ek, doxorubicin 
shoul d be reduced to 75% of the starting dose (that is, to approximately  60mg/m 2).  If a pati ent 
experiences a second incidence of neutropenic fever/infection or has another epi[INVESTIGATOR_119988] [ADDRESS_1153991] ing >1 week, then a second dos
e reduction to 45 mg/m2will be necessary .  
Therapeut ic and prophylact ic use of pegfilgrast im (Neul asta®)or other G -CSFs will be allowed 
per current American Societ y of Clinical  Oncol ogy (ASCO; Smit h et al . 2006) and Nati onal 
Com prehensive Cancer Network (NCCN) guidelines (NCCN 2014) .  For pati ents wi th Grade 4 
ANC wi thout fever/infect ion lasting less than 1 week, retreatment will be allowed at the 
investigator’s discret ion with the f ull dose of doxorubicin (75 mg/m2)with recommended use o f 
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 38
LY3012207G-CSFs per cur rent ASCO guidelines (Smit h et al . 2006).  See Table JGDM. 4for doxorubi cin 
dose m odificat ion for neutropenia.
Table JGDM. 4. General Guidelines for Doxorubicin Dose Modification Due to 
Neutropenia
Toxicity Required Dose Modification
ANC <1000 cells/ L No doxorubicin administered; treatment cycle delayed.
At pretreatment:
If  Grade ≥3 neutropenic fever/infection has occurred Approximately 60 mg/m 2doxorubicin.
If Grade 4 neutropenia lasting longer than 1 week 
has occurred Approximately 60 mg/m 2doxorubicin.
Grade 4 ANC without fever/infection Retreatment with doxorubicin at full dose at 
investigator’s discretion with recommended use of 
prophylactic G -CSFs.
Second incidence of either:  
1) Grade ≥3 neutropenic fever/infection
2) Grade 4 neutropenia lasting longer than 1 weekSecond dose reduction to 45 mg/m 2.
Abbreviations :  ANC = absolute neutrophil count; G -CSF = granulocyte colony -stimulating factor.
[IP_ADDRESS].2.2. Cardiovascular Toxicity
Cardi otoxi city is a recognized risk of doxorubicin that increases with higher cumulat ive drug 
exposure.  Cardiac mo nitoring is conducted by  a combinat ion of monitoring of clinical 
param eters, E CG, and ECHO/MUGA scan s.
Electrocardiogram changes, arrhy thmias, tachycardia, and/or chest pain should be managed 
according to clinical practice based on the specific findings.
Patients will  undergo baseline LVEF determinat ion by [CONTACT_123550].  This e valuat ion 
may be repeated at any  time during the study  if clinically indicated.  If there is a decrease in 
LVEF of 10% and below the lower limit of normal ,if there is an abso lute decrease of 20%, or 
if the abso lute LVEF decreases to or below 40%, then doxorubicin will be discont inued.  
Doxorubi cin shoul d also be di scont inued if the patient develops Grade 3 or 4 left ventricular 
systolic dysfunction (symptomat ic congest ive heart failure).  Allsuch changes should be 
reported as AEs.  If doxorubicin is discont inued for the above changes in LVEF, then ol aratum ab 
must be discont inued as well (see Section [IP_ADDRESS] ).  
The di agnost ic met hod used at baseline for cardiovascular assessments (for example ,ECHO or 
MUGA scans) should be the same method used throughout the study , unless there i s clinical or 
instrum ental  evidence that further invest igations are needed.
[IP_ADDRESS].2.3. Hepatic Impairment
Doxorubi cin is contraindicated in patients with severe hepat ic impairment (Child- Pugh Cl ass C 
or total serum  bilirubin >5.0 m g/dL).   
Refer to Section [IP_ADDRESS] for addi tional information.  
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 39
LY30122077.[IP_ADDRESS].4. Nonhematologic Toxicity
Perm anent discont inuat ion of doxorubicin should be considered for any pat ient experiencing 
Grade [ADDRESS_1153992] igator feels re -
dosing of doxorubicin is appropriate (except for Grade 4 cardiotoxi cities and Grade 4 bilirubin 
increase which require mandatory  discont inuat ion [see Section [IP_ADDRESS].2.2 and 
Secti on7.[IP_ADDRESS].3 ]), treatment may only resume after consultation wit h the Lilly study  
physician, with the dose reduced to 60 mg/m² (or less if agreed by [CONTACT_831433]). If Grade 4 toxicit y recurs after therapy resumes, doxorubicin treatment will be 
perm anent ly discont inued.
For appropriate management of cardiac toxicit ies and hepat ic impairment ,refer to Section 
[IP_ADDRESS].2.2 and Section [IP_ADDRESS].2.3 . 
7.3. Method of Assignment to Treatment
Patients who m eet all cri teria for enrollment will be assigned to receive treatment.  After the 
patient si gns the IC F, the si te will register the patient in the Interactive Web Response System 
(IWRS), which is web -based and accessible 24 hours a day.  The IWRS registration consists of 
assigning the patient a unique study  identificat ion number.  Once the patient is registered through 
the IWRS, he/she is considered to be enrolled in the study .  
7.3.1. Selection and Timing of Doses
A cycle is define d as an interval of 21 days (a cycle m ay be delayed up to 3 days due to holidays, 
weekends, bad weather, or other unforeseen circumstances wit hout being counted as a protocol 
deviat ion). 
The dose of olaratumab to be administered will be determined by [CONTACT_95850]’s weight 
in kilograms on Day  1 and Day  8 of each cycle.  The dose of doxorubicin to be administered will 
be determined by [CONTACT_240222]'s body surface area at t he beginning of each cycle.  If the 
patient’s weight does not fluctuate by  10% (increase or decrease) from the wei ght used to 
calculate the pri or dose, the olaratum ab dose will  not need to be recalculated.  A 5% vari ance in 
the calculated total  dose will be allowed for ease of dose administration.
A pat ient may cont inue to receive study treatment unt il he or she has received a maximum o f 
6cycles o f olaratum ab in co mbinat ion with doxorubicin, or until he or she meets 1 or more of 
the specified reasons for discont inuat ion (as described in Sect ion6.3.2 ).
7.4. Blinding
This is an open -label study .
7.5. Concomitant Therapy
All conco mitant medications should be recorded throughout the patient’s participat ion in the 
study .
Concomitant medicat ions and supportive care therapi[INVESTIGATOR_831414] o f 
discontinuat ion and at the 30 -day short -term follow
-up visit.
I5B-MC-JGDM (c)Phase [ADDRESS_1153993] inhibitors ( for example , zoledroni c acid or pamidronate) for treatment 
of bone metastases will be permitted while pat ients are on study  treatm ent.  However, the 
osteocl ast inhibitor denosumab is a monoclonal antibody  and coul d confound safet y analysis in 
the study  if the pati ent experiences a hypersensit ivity reacti on to denosum ab. Therefore, 
concomitant use of denosumab will not be permitted.
Appropriate documentation for all forms of premedicat ions, support ive care, and concomitant 
medicat ions (for example, medicat ions such as sedatives, ant ibiotics, analgesics, ant ihistamines, 
corticosteroi ds,orerythropoi etin; procedures such as paracentesis, or thoracentesis; or blood 
products such as blood cells, platel ets, or fresh frozen plasma transfusio ns) m ust be captured on 
the eCRF.
If doxorubicin premedicat ion is required prior to the doxorubicin infusio n, this must be done 
after the com pletion of olaratumab infusion, not before the ol aratum ab infusi on.
7.5.1. Supportiv e Care
Patients shoul d receive full supportive care, if necessary .  Pati ents will  receive supportive care as 
judged by  [CONTACT_24018].  If it is unclear whether a therapy  shoul d be regarded as 
supportive care, the invest igator should consult with the Lilly CRP.  Use of any supportive care 
therapy  must be captured on the eCRFs.
[IP_ADDRESS]. Dexrazoxane
Starti ng wit h the first cy cle of combinat ion therapy (that is, Cycle 2) , dexrazoxane may  be 
administered IV at the investigator’s discret ion according to instructions provided in the 
pharmacy manual  for thi s study , beginning within 30 minutes prior to each doxorubicin infusio n 
for the prevent ion of cardiotoxicit y.  It is reco mmended that all pat ients receiving 5 or more 
cycles of doxorubi cin receive dexrazoxane.  Investigators should consult the dexrazoxane 
inform ation provi ded in the pharmacy manual  for this study  for administrati on informat ion 
(including warnings, precaution s, contraindicat ions, adverse react ions, and dose modifications).
Asthe dose of dexrazoxane administered is dependent on the dose of doxorubicin administered, 
any dose m odificat ions to doxorubicin will require a corresponding dose modificat ion to 
dexrazox ane in order to m aintain a dosage ratio of 10:1 (dexrazoxane:doxorubicin).
[IP_ADDRESS]. Granulocyte -Colony Stimulating Factors and Erythroid Growth Factors
Following the first dose of doxorubicin treatment, the use of G -CSFs such as pegfilgrastim and 
erythroid stimulat ing factors (for example, erythropoiet in) are permitted, including prophylact ic 
use, during invest igational therapy  at the di screti on of  the invest igator, according to ASCO 
guidelines (Smit h et al . 2006) and NCCN guidelines (NCCN 2014).
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 41
LY30122077.5.1.3. Transfusion of Bloo d Products
Transfusio ns of red blood cells, platelets, or other blood products are permitted at the 
investigator’s discret ion, but may not be used to meet hematologic criteria for inclusion in the 
study  (refer to Secti on 6.1.1 , inclusion criterion #9).
[IP_ADDRESS]. Anti-emetic Therapy
Both prophylactic and symptom -directed ant i
-emetic therapy  are recommended and should be 
used in accordance wit h institutional guid elines (when existent) and/or at investigator’s 
discreti on.
7.5.2. Prohibited Therapi[INVESTIGATOR_240183] , radiati on therapy , biologic response m odifiers, or other 
investigat ional or approved anticancer agents may  not be administered to patients on this study .  
Palliat ive radiat ion to symptomat ic sites of disease will not be permitted while on study.
[IP_ADDRESS]. Effect of CYP3A4, CYP2D6, and P -gp Inhibitors and Inducers on 
Doxorubicin
Doxorubi cin is a major substrate of cy tochrom e P450 (CYP )3A4 and CYP2D6, and P -
glycoprotein (P -gp).  Clinically significant interactio nshave been reported with inhibitors of 
CYP3A4, CYP2D6, and/or P -gp (for example, verapamil), result ing in increased conc entrati on 
and clinical effect of doxorubicin.  Inducers of CYP3A4 (for example, phenobarbital, phenyto in, 
St. John’s Wort) and P -gp inducers may decrease the concentration of doxorubi cin.  Avoi d 
concurrent use of doxorubicin with inhibitors and inducers o f CYP3A4, CYP2D6, or P -gp.  
Attachm ent [ADDRESS_1153994] igational sites by  [CONTACT_327788].  As a result, treatment compliance is ensured.   Treatment compliance will 
be monitored by  [CONTACT_53973] y records, and treatm ent administration data are recorded in 
the pati ent’s m edical  record and eCRF.  An invest igator is required to prepare, maintain, and 
record all observat ions and other data pertinent to the invest igation on each individual treated in 
this clinical tri al.  All data reported on the eCRF must be derived from source documents and be 
consistent with the source documents.
7.6.1. Evaluable Patients
Evaluable patients are those with adequate bio marker sam ples who have a baseline (pre-
monotherapy )and at least [ADDRESS_1153995] 1 dose of study  drug.
If the patient is nonco mpliant during olaratum ab monotherapy  (Cycle 1) and does not undergo 
the post -olaratum ab m onotherapy  biopsy  or the C1D1 pre -dose and C2D1 predose whole blood 
sample collect ion due to reasons other than drug- related toxicit y, he or she will be considered 
nonevaluable for the primary  object ive.  These patients may be replaced to ensure that 35
I5B-MC-JGDM (c)Phase [ADDRESS_1153996] -olaratum ab m onotherapy  biopsy,
and the associated C2D1 predose whole blood sample co llection.
I5B-MC-JGDM (c)Phase [ADDRESS_1153997] to 
follow-up.  Frequency  of AEand SAE follow-up evaluat ion is left to the discret ion of the 
investigator.
The timing of all safet y evaluat ions is shown in the Study  Schedule ( Attachment 1 ).  Section 
[IP_ADDRESS] presents a summary of AE and SAE reporting guidelines.  Table JGDM. 5shows the 
database or system used to store AE and SAE data .
8.1.2. Adverse Events
Lilly has standards for reporting AEs that are to be fo llowed regardl ess of applicable regulat ory 
requi rements that m ay be less stringent.  A clinical study  AE is any untoward medical occurrence 
in a pati ent or clinical invest igation subject administered a pharmaceut ical product and which 
does not necessarily  have a causal  relati onship wi th this tr eatment.  An AE can therefore be any 
unfavorable and unintended sign (including an abnormal laboratory  finding), symptom, or 
disease tem porally associ ated wi th the use of m edicinal (invest igational) product, whether or not 
related to the medicinal (invest igational) product.   
Any clinically  significant findings from labs, 
vital sign m easurements, and so on that occur should also be reported to Lilly or its designee as 
an AE.  Lack of drug effect is not an AE in clinical studies because the purpose of the cli nical  
study  is to establish drug effect.
The invest igator, monitor, and sponsor will review the collected data regularly for evidence of 
AEs. All pat ients will be assessed routinely for AEs as outlined in the Study Schedule
(Attachm ent 1 ).  The NCI -CTCAE Versi on 4.[ADDRESS_1153998] ing the appropriate System Organ Class and assessing severit y grade based on the intensit y 
of the event.  Note that both CTCAE term (actual or coded) and severit y grade m ust be selected 
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 44
LY3012207by [CONTACT_831434] ( CRF ).  This collection is in 
addition to verbat im text used to describe the AE.
In addit ion to collect ing the AE verbat im, the CTCAE term, and the CTCAE severit y grade, AE 
verbat im text will al so be mapped by [CONTACT_92354] (MedDRA) dict ionary.
Cases of pregnancy that occur during maternal or paternal exposures to study  shoul d be r eported.  
Data on fetal outcome and breast feeding should be collected, if feasible, for regulatory  reporti ng 
and drug safet y evaluat ion.
Upon docum entati on of  pregnancy , the pati ent m ust be rem oved from  the study  and treatment 
with study  drugs m ust be stop ped immediately.
For all enrolled pat ients, study  site personnel will record the occurrence and nature of each 
patient’s preexist ing condit ions, including clinically  significant si gns and symptoms of the 
disease under treatment in the study .  While the pati ent is on study , site personnel will record any  
change in these preexist ing condit ion(s) and the occurrence and nature of any  AEs.  In addit ion,
all AEs related to protocol  procedures will bereported to Lilly or desi gnee.
If a patient ’s dosage is reduced or treatment is discontinued as a result of an AE, study  site 
personnel must clearly  report to Lilly or its desi gnee via eCRF the ci rcumstances and data 
leading to any  such dosage reduction or discont inuation of treatm ent. 
Invest igators will be instructed to report to Lilly or its designee their assessment of the potential 
relatedness of each AE to protocol procedure and/or study drug via eCRF .
The invest igator decides whether he or she interprets the observed AEs as ei ther rel ated to 
disease, study  medicati on, study  procedure, or other concomitant treatment or pathologies.  To 
assess the relat ionship of the AE to the study  drug, the foll owing te rminologies are defined:
Related :  a di rect cause and effect relat ionship between the study  treatm ent and 
the AE i s likely.
Possibly related :  a cause and effect relat ionship between the study  treatm ent and 
the AE has not been demonstrated at this time and is not probable, but is also not 
impossible.
Unrelated :  without questi on, the AE i s defini tely not associ ated wi th the study  
treatm ent.
As per Lilly’s standard operating procedures ,all “related” and “possibly  related” AEs and SAEs 
will be defined as rel ated to study  drug.
[IP_ADDRESS]. Serious Adverse Events
Planned surgeries should not be reported as SAEs unless the underlying medical condit ion has 
worsened during the course of the study .
An SAE is any  AEduring thi s study  that resul ts in one of the fo llowing outcom es:
death
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 45
LY3012207initial or prolonged inpatient hospi[INVESTIGATOR_3094] (except for study  drug 
administration)
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabili ty/incapacit y
congenital ano maly/birth defect
considered significant by  [CONTACT_92355].
Important m edical events that may not result in death, be life -threatening, or require 
hospi [INVESTIGATOR_831415] c onsidered SAEs when, based on appropriate medical judgment, they  
may jeopardize the patient and may require medical or surgical intervent ion to prevent one of the 
outcom es listed in this definit ion. 
Serious adverse events due to dise ase progression, including death, should not be reported unless 
the invest igator deems them to be possibly related to the study  drug.
Study  site personnel  must al ert Lilly or its desi gnee of  any SAE within [ADDRESS_1153999] igator 
awareness o f the event via a sponsor -approved method.  If alerts areissued via telephone , they
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 24-
hour notificat ion requirement refers to the init ial SAE informat ionand all fo llow-up SAE 
inform ation.  Attachment 5 provides r ecommendatio ns for reporting SAE s.
When a condit ion related to study treatment necessitates medical or surgical intervent ion to 
precl ude ei ther perm anent impairment of a body  function or permanent damage to a body  
structure, the seri ous outcom e of “requi red intervent ion” will be assigned.
If an i nvest igator becomes aware of SAEs occurring after the patient’s participation in the trial 
has ended, and the invest igator believes that the SAE is related to a protocol procedure or study 
drug, the invest igator should report the SAEs to the sponsor and th e SAEs will be entered in the
Lilly Safety  System .
Inform ation on SAEs expected in the study  popul ation independent of drug exposure and that 
will be assessed by  [CONTACT_248178].  
[IP_ADDRESS]. Adverse Event and Serious Adverse Event Reporting
Data on SAEs that occur before the end of trial will be stored in the col lection database and in 
the Lilly  Safety System .
[IP_ADDRESS].1. Prior to Administration of Study Drugs
Although all AEs after signing the ICF are recorded in the CRF, SAE reporting begins after the 
patient has signed the ICF and has received study  treatm ent. However, if an SAE occurs after 
signing the ICF, but prior to receiving study  treatment, i t needs to be reported ONLY if it is 
considered reasonably  possibly  related to study  procedure.
[IP_ADDRESS].2. On Study Treatment
All AEs and SAEs, regardless of relatedness to study  drugs or protocol  procedures, occurring 
while the patient is receiving study  drug m ust be reported to Lilly or its designee.  A patient is 
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 46
LY3012207considered to be receiving study  drug from  the time he/she receives the first dose of study  drug 
to when he/she receives the last dose of study  drug.
[IP_ADDRESS].3. Follow -Up Visit
All AEs and SAEs , regardl ess of relatedness to study  drugs or protocol  procedures, occurring 
during the fo llow-up visit (Visit 801) must be reported to Lilly or its designee . The fo llow-up 
visit begins the day  after the pati ent and the invest igator agree that the patient will no longer 
continue study  treatm ent.  At the end of the fo llow-up vi sit, the pati ent will be required to have 
specific safet y assessments ( Attachment 1 ).  The timing of these safet y assessments is 30 ± [ADDRESS_1154000] dose of study  drug .
Following the safet y assessments, which mark the end of the fo llow-up visit (Visit 801), the 
patient will continue into long-term follow -up unt il disease progression .  Any ongoing AE or 
SAE considered possibly  related to study  drug shoul d be f ollowed durin g the l ong-term follow -
up.  In this instance, the patient should be fo llowed in subsequent fo llow-up visit s (Visit 802, 
Visit 8XX )until the event is reso lved, oris no longer consi dered to be drug -related, orbecomes 
stable ,or returns to baseline, a new treatm ent is initi ated for the patient, or the patient dies or is 
lost to foll ow-
up.
If it is deemed to be in the best interest of the patient to start a new ant icancer treatment prior to 
the scheduled end of the fo llow-up visit, the fo llow-up vi sit durati on may  be shortened. In this 
case, the fo llow-up assessments should be co mpleted prior to the init iation of the new therapy.
After the fo llow-up visit (Visi t 801), AEs are not required to be reported unless the invest igator 
feels th e AEs were related to either study  drug, drug delivery  system , or a protocol  procedure. If 
an invest igator becomes aware of anySAEsbelieved to be related to protocol procedures or 
study  drug , the investigator should report the SAE to the sponsor, and the SAE will be entered in 
theLilly Safet y System .
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) are SAEs that are not listed in the
DCSI and that t he investigator identifies as related to study drug or procedure.  The [LOCATION_002] 
21 CFR 312.32, the European Unio n Clinical Trial Directive 2001/20/EC ,and the associated 
detailed guidances or nati onal regulatory  requi rements in parti cipat ing countries requi re the 
reporting of S[LOCATION_003]Rs.  Lilly has procedures that will be fo llowed for the recording and expedited 
reporting of S[LOCATION_003]Rs that are consistent with glo bal regul atory  regul ationsand the associated 
detailed guidances.
[IP_ADDRESS]. Summary of AE/SAE Reporting Guidelines
Table JGDM. 5summarizes t he AE and SAE reporting guidelines .
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 47
LY3012207Table JGDM. 5. Adverse Event and Serious A dverse Event Reporting Guidelines
Period Types of AEs/SAEs to be ReportedCollection 
DatabaseLilly Safety 
System
Baseline (pretreatment) Preexisting conditions x
All AEs x
SAEs related to protocol procedures x x
Study treatment period All AEs x
All SAEs x x
30-day short -term 
postdiscontinuation follow -up All AEs x
All SAEs x x
Long -term postdiscontinuation 
follow -up All SAEs related to protocol procedures 
or study  treatmentx x
After the patient is no longer 
participating in the study (that is, no 
longer receiving study treatment and 
no lo nger in long-term 
postdiscontinuation follow -up)All SAEs related to protocol procedures 
or study  treatment that the investigator 
becomes aware ofx
Abbreviations:  AE = adverse event; SAE = serious adverse event.
8.1.3. Other Safety Measures
[IP_ADDRESS]. Electrocardiograms
For each patient, 12 -lead ECGs will be collected according to the Study  Schedule (Attachm ent 
1).  Patients must be supi[INVESTIGATOR_17044] [ADDRESS_1154001] ion of more ECGs than expected at a particular time point is allowed when needed to 
ensure high qualit y records.
Electrocardiograms will be interpreted by  a qualified physician (the investigator or q ualified 
designee) at the site as soon after the time of ECG collect ion as possible, and ideally while the 
patient is st ill present, to determine whether the patient meets entry criteria and for immediate 
patient management, should any  clinically relevant findings be identified.   Secti on 9.2.[ADDRESS_1154002] ion and storage. 
After enro llment, if a clinically significant increase in the QT/corrected QT interval (QTc) from  
baseline, or other clinically significant quantitative or qualitative change from baseline, is 
present, the invest igator will assess the patient for symptoms (for example, palpi[INVESTIGATOR_53895], near 
syncope, syncope) and to determine if the pat ient can cont inue in the study .  The invest igator or 
qualified designee is responsible for determining if any change in pat ient management i s needed 
and must document his/her review of the ECG printed at the time of evaluation.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 48
LY3012207Table JGDM. 6provi des Bazett’s QT heart rate correction formula.   Table JGDM. 8.7provides 
Fridericia’s QT correcti on formulafor pati ents wi th bundle branch block.
Table JGDM. 6
. Bazett’s QT Heart Rate Correction Formula
Formula Bazett’s QTc=QT (HR/60)1/2=QT (RR)–1/[ADDRESS_1154003] HRs
Under-corrects QT at low HRs (the risk of TdP which 
frequently occurs at low HRs, may not be evident)
Abbreviations:  QTc = corrected QT interval; HR = heart rate; RR = duration of ventricular cardiac cycle; 
TdP = torsade de pointes (a polymorphic ventricular tachycardia). 
Table JGDM.8.3 Fridericia’s QT Correction Formula
Formula QTcF=QT/(RR)1/3
Abbreviations:  QT = ECG interval measured from the onset of the QRS complex to the offset of the T wave ; 
QTcF =QT interval corrected for heart rate using Fridericia’s formula ;RR = time between corresponding po ints 
on 2 consecutive R waves on ECG .
[IP_ADDRESS]. Echocardiograms /MUGA Scans
An ECHO orMUGA scan is required wit hin 28 days prior to enrollment for all patients.  
Thereafter, ECHO or MUGA scans , whichever technique was used init ially (as described in 
Section [IP_ADDRESS].2.2 ),must be performed at the end of Cycles 5and 7, and when clinically
indicated.  For patients with LVEF <50% or other cardiac dysfunct ion, perform more frequent ly, 
if clinically indicated. After Cy cle 7(for patients with resting LVEF ≥50%), an ECHO or 
MUGA scan shoul d be obtained at the 30 -day follow-up visit (refer to the Study  Schedule
[Attachm ent 1 ]).  
Patients who stop doxorubicin prior to Cy cle 7will undergo cardiac monitoring assessment at the 
30-day follow - up visit (refer to the Study  Schedule [ Attachment 1]) wi th whichever technique 
(ECHO or MUGA scan )was used init ially (as des cribed in Sect ion7.[IP_ADDRESS].2 ).
8.1.4. Safety Monitoring
The Lilly CRP /clinical research scientist ( CRS )will monitor safety  data throughout the course of 
the study , including a safet y review conducted after the f irst [ADDRESS_1154004] completed C ycle 2 
of treatm ent. 
I5B-MC-JGDM (c)Phase [ADDRESS_1154005], and review:
trends in safety  data
laboratory  analy tes
AEs, including cardiac events such as:
omyocardial  failure ordysfunct ion
omyocardial  ischemia or infarct ion
oarrhy thmias
ocardi ovascular insufficiency
adverse events of special interest ( AESIs; as defined in Sect ion8.1.4.1 )
If a study  patient experiences elevated ALT 5× ULN and elevated total bilirubin 
2×ULN, clinical and laboratory  monitoring should be init iated by  [CONTACT_3170]. 
Details for hepat ic monitoring depend upon the severit y and persistence of observed laboratory  
test abnorm alities. To ensure patient safety and comply wit h regulatory  guidance, the 
investigator is to consult with the Lilly CRP /CRS regarding collect ion of specific reco mmended 
clinical informat ion and fo llow-up laboratory  tests (seeAttachm ent 3 ).  
[IP_ADDRESS]. Adverse Events of Special Interest
Adverse events of special interest are events that have been ident ified as safet y signals during 
preclinical or early  clinical tri als or based on class effects of similar drugs.  These events will be 
monitored prospectively in the clinical developmental pr ogram .  Each event is defined by  a 
careful assessment and groupi[INVESTIGATOR_831416]. 
AESI for olaratumab
IRRs
AESI for combination of olaratumab and doxorubicin
Cardi ac arrhy thmias and cardiac dysfunct ion
Refer to Section 7.2.3 for special treatment considerations for dose delay, modifications, and 
discontinuat ions from  olaratum ab and /ordoxorubicin, including AEs of conce rn or AESIs .
8.1.5. Complaint Handling
Lilly co llects complaints on study  drugs used in clinical studies in order to ensure the safet y of 
study  participants, m onitor quali ty, and f acilitate process and product improvements.
Patients will  be instructed to contact [CONTACT_81129] a 
complaint or probl em wi th the IPso that the situation can be assessed.
Com plaint s related to doxorubicin and/or dexraz oxane or concomitant drugs are reported directly 
to the m anufacturers of those drugs in accordance with the package insert.
I5B-MC-JGDM (c)Phase [ADDRESS_1154006] igator or his/her designee is responsible for handling the fo llowing aspects of the 
complaint process in accordance with the instructions provided for this study :
recording a complete descript ion of the product complaint reported and any associated 
AEs using the study -specific co mplaint form s provided for this purpose
faxing the completed product complaint form wit hin [ADDRESS_1154007] igation, he/she will return a copy  of the 
product complaint form with the product.
8.2. Sample Collection and Testing
Attachm ent [ADDRESS_1154008] ion of bio marker, PK, and 
immunogenicit y blood sam ples.
8.2.1. Samples for Study Qualification and Health Monitoring
Blood, urine ,and t issue samples wi ll be co llected to determine whether patients meet 
inclusio n/excl usion criteria and to m onitor pati ent heal th.
Invest igators must document their review of each laboratory  safety  report.
Samples co llected for spec ified laboratory  tests will  be destroy ed wi thin [ADDRESS_1154009] results.  Tests are run and confirmed prompt ly whenever scient ifically 
appropriate.  When scientific circumstances warrant, however, it is acceptable to retain samples 
to batch the tests run, or to retain the samples until the end of the study to confirm that the results 
are valid.  Certain samples may be retained for a longer period, if necessary, to comply wit h 
applicable laws, regulat ions, or l aboratory  certificati on sta ndards.
Secti on
 [IP_ADDRESS] specifies blood sample requirements for study  qualificat ion.  
Secti on [IP_ADDRESS] specifies t umor tissue sample requirements for study qualificat ion. 
8.2.2. Samples for Drug Concentration Measurements 
Pharmacokinetics
Pharmacokinet ic samples will be co llected as specified in th e Biomarker, PK,and 
Immunogenicit y Blood Sampling Schedule 
(Attachment 4 ). 
[IP_ADDRESS]. Pharmacokinetic Samples
At the visit s and t imes specified in the Study Schedule ( Attachment 1 )and in the Bio marker, PK, 
and Immunogenicit y Blood Sampling Schedule (Attachm ent 4 ), samples of approximately  3mL 
of who le blood will be drawn into tubes to perform olaratumab serum PK measurements.   A 
maximum o f 3samples per drug m ay be collected at addi tional time points during the study  if 
warranted and agreed upon between both the investigator and Lilly.  Instructi ons for the 
I5B-MC-JGDM (c)Phase [ADDRESS_1154010] ion and handling of blood samples will be provided by [CONTACT_11007] .  The actual  date and time 
(24-hour clock time) of each sampling will be recorded.
These samples will be analyzed at laboratories designated by [CONTACT_456].  Serum concentrations 
of olaratum ab will be assayed using a validated enzyme- linked immunosorbent assay method.  
Bioanaly tical samples collected to m easure IPconcentration will be retained for a maximum of 
1year fo llowing last pati ent visi t for the study  and will  be stored at facilit ies designated by  [CONTACT_11007] .
8.2.3. Samples for Biomarker s
As part of Lilly’s ongoing efforts to understand the relat ionship between cancer , genet ics, and
response to therapy , this study  will analyze bio markers relevant to drug targets, disease process, 
pathways associated with STS and/or cancer -related cond itions, immune cells/immune and 
tumor microenvironment functioning wi thin the disease state and MOA of olaratum ab or 
doxorubi cin. 
The primary  object ivesof this study  are to enumerate whole blood CTCs and to characterize 
PDGFR α,PDGFR β,and canonical ligand s (PDGF -A, B, C ,and D)expressio n changes pre -and 
post-olaratum ab m onotherapy  in tumor tissue inpatients wi th potenti ally resectable STS.  
There will be mandatory  collection o f tumor tissue sam ples pre-and post -olaratumab 
monotherapy and an opti onal collect ion of tum or tissue at the end of the patient’s study  
treatm ent,or when the patient undergoes a surgical resection ,for study object ives relating to 
PDGFR expressio n and rel ated pathway s,and to the bio markers in the primary object ive and 
clinical outcomes.  The study  may be used for rel ated research methods or validat ion of 
diagnosti c tool s or assays.
Collect ion of samples for bio marker research is a mandatory  part of this study .  Blo odand tissue
samples will be co llected .  
Requi red samples for bi omarker research to be collected from all pat ients in this study  are the 
following:
blood (see Section [IP_ADDRESS] and Section 8.2.4 )
tumor tissue ( see Section [IP_ADDRESS] )
Sample collect ion including blood and tumor tissue will occur at specified t ime points as 
indicated in the Study  Schedule ( Attachment 1 ).These samples are also described in the 
following sect ions.
It is possible that bi omarker data has already  been generated from  samples that were collected 
and analyzed prior to enrolling in this trial.  This may  include data generated from genet ic 
analyses.  If available, this data may  be requested from  medical records for use in the research 
described in the fo llowing sect ions.
Samples may  be stored for a maximum of [ADDRESS_1154011] pati ent visi t for the study .
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 52
LY30122078.2.3.1. Blood Samples
Who le blood sam ples are requi red for all patients in order to participate in this study  for 
biomarker research:
newly obtained peripheral whole blood specimens will be co llected 
specifically to enumerate CTCs .  These specimens will be co llected at C1D1 
(predose), C1D8 (predose), C2D1 (predose), C2D8 (predose), C3D1 
(predose), and at the end of the patient’s study  treatm entor at the time o f 
surgi cal resect ion.  Ref er to Attachment 4 for details. 
blood ( ethylenediaminetetraacetic [ EDTA ]plasma, serum) samples for 
nonpharmacogenet ic biomarker research wil l be collected .  Refer to 
Attachm ent 4 for details.
Newly obtained peripheral who le blood specimens are to be collected specifically to enumerate 
CTC s.  Sequenti ally collected blood specimens will be used for CTC detection andenumerat ion.  
The primary  analysis of these samples will be focused on the relationship between pre -
olaratum ab m onotherapy  and on -treatm ent (post -olaratum ab m onotherapy  treatm ent)CTC 
counts .These samples may be used for other exploratory analyses and further mo lecular 
characterizat ion.
Addit ional blood (EDTA plasma, serum) samples for nonpharmacogenetic bio marker research 
will be co llected .  These s amples will be examined fo r biomarkers related to STS, immune 
cells/immune and tumor microenviro nment funct ioning within the disease state and/or cancer -
related condi tions, variable response to olaratumab and/or doxorubicin, and the MOA of 
olaratum ab or dox orubi cin.  Potenti al phar macodynamics and/or circulat ing markers may 
include, but are not limited to ,PDGF receptors, canonical ligands ( PDGF -A, B, C ,and D)
,and 
downstream signaling pathways .  Biomarker assays m ay be perform ed on these samples to 
evaluate systemic immune modulat ion and changes in immune cell infiltration, activat ion, 
modulat ion, microenvironment ,and changes in stromal and tumor bio logy in response to study  
treatm ent.
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by [CONTACT_327790].  Sam ples will  be retained for a 
maximum o f [ADDRESS_1154012] igation of variable response that may not be observed unt il later in the drug 
development or when the drug is commercially available for a shorter period if local regulat ions 
and/or ERBs impose sh orter tim e limits.
[IP_ADDRESS]. Tumor Tissue 
Collect ion of the fo llowing tum or tissue samples is mandatory for all patients:
newly obtained biopsy  specimens taken from the primary  tumor lesionpre-and post -
olaratum ab m onotherapy  treatment will be co llected .  The pretreatment tissue biopsy is to 
be perform ed wi thin the screening period.  The posttreatment tissue biopsy  is to be 
perform ed after com pletion of the lead -in cycle o f olaratum ab m onotherapy  and pri or to 
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 53
LY3012207the init iation of co mbinat ion therapy  (Cycle 2).   Refer to Attachment [ADDRESS_1154013] ion of  the f ollowing tumor tissue samples isoptional for all patients:
biopsy specimen collected at the end of the patient’s study  treatm ent.  Refer to
Attachm ent 1 for addi tional details.  If clinically feasible, this biopsy  shoul d be taken 
from the same primary  tumor lesion.
tumor tissue from  any post -therapy  surgi cal resect ionmay also be collected and provided.
While this specimen is optional, itis expected this sample will be sent for analysis.
Sites shoul d examine samples to determine adequacy  of tumor tissue using their local laboratory  
procedures prior to the first dose of olaratumab monotherapy and again prior to the first dose of 
combinat ion therapy .  If addi tional tumor biopsies are collected as part of clinical care, they  
shoul d be submi tted, al ong wi th local pathol ogy reports, for further analysis. 
Details for the handling and shippi[INVESTIGATOR_831417] a s eparate 
docum ent.  The ti ssue samples will be obtained using appropriate method.  Tumor tissue should 
be submitted as a newly acquired excisio nal or core needle (minimum 18 gauge) biopsy  in 
formalin (10% neutral buffered).  Cy tological or fine -needle aspir ation specimens are not 
acceptable.  Due diligence should be used to make sure that tumor sample (not a normal adjacent 
or a tum or margin sample) is provided.  Pathology  reports accom panying tissue may  also be 
requested.  The reports must be coded with the patient number.  Personal identifiers, including 
the pati ent’s name [CONTACT_133430], must be removed from the inst itutional pathol ogy notes pri or to 
submissio n.  
Collected tum or sam ples will be used for research on the drug targets, disease process, pathway s 
associ ated wi th STS and/or cancer -related cond itions, immune cells/immune and tumor 
microenvironment functioning wit hin the disease state and/or cancer -related condi tions, MOA of 
olaratum ab or dox orubi cin, and/or research methods or in validating diagnosti c tool s or assay (s) 
related to cancer .  The primary  analysis o f these tum or tissue samples will be focused on the 
assessment of expressio n level change of PDGFRα ,PDGFR β,and canonical ligands (PDGF A, 
B, C, andD)pre-and post -olaratum ab m onotherapy treatm ent. The relationship of baseline 
expressio n and expressio n level changes from  baseline of these markers will also be evaluated . 
In addit ion, as a part of exploratory  analysis mutati on profiling, gen e expressio n, sequencing 
and/or IHC may be performed on these tissue samples to evaluate changes in immune cell 
infiltrat ion, activat ion, modulation, microenvironment and changes in stromal and tumor bio logy 
in response to study  treatm ent.  This may  include evaluat ion of bio markers related to ,but not 
limited to, PD1 ligand and tum or infiltrating lymphocy tes on tum or and stroma cells.
The samples will be coded with the patient number and stored for up to a maximum [ADDRESS_1154014] pati ent vi sit for the study  at a f acility selected by  [CONTACT_456].  The samples and any 
data generated from them can only be linked back to the patient by  [CONTACT_240241].  
The durati on allows the sponsor to respond to regulatory  requests related to the study  drug.  
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 54
LY3012207Samples will  be destroy ed according to a process consistent with local regulat ion.
[IP_ADDRESS]. Imaging Studies
A pre -and post -olaratum ab m onotherapy  posi tron emissio n tom ography  (PET) scan will be 
collected for exploratory  analyses at times specified in Attachm ent [ADDRESS_1154015] a pati ent’s response to therapy .  
Variable response to therapy  may be due to genetic det erminants that impact drug absorption, 
distribut ion, metabo lism, and excretion, the mechanism of act ion of the drug, the disease 
etiology and/or the m olecular subt ype of the disease being treated.  Therefore, where local 
regul ations and ERBs allo w, a bl oodsample will be collected for pharmacogenet ic analysis
(Attachm ent 1 ).  
In the event of an unexpected AE or the observat ion of unusual response, the pharmacogenetic 
biomarker samples may  be genoty ped and analysis may  be perform ed to eval uate a genet ic 
associ ation with response to olaratumab and/or doxorubi cin.  These invest igations m ay be 
limited to a focused candidate gene study  or, if appropri ate, genom e-wide analysis may  be 
perform ed to i dentify regio ns of the geno me associated w ith the variabilit y observed in drug 
response.  The pharmacogenet ic biomarker samples will only be used for invest igations related 
to disease and drug or class o f drugs under study  in the context of thi s clinical program.  They  
will not be used for broad e xploratory unspecified disease or populat ion genetic analysis.
The samples will be coded with the patient number and stored for up to a maximum [ADDRESS_1154016] anti -drug ant ibodies in the presence of olaratum ab.  Ant ibodies may be 
further characterized and/or evaluated for their abilit y to neutralize the activit y of olaratum ab.
Samples may  be stored for a m aximum of [ADDRESS_1154017] ive of the study  is to docum ent any ant itumor activit y.  Ref er to Attachment 1
for details regarding the timing of specific efficacy measures.  
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 55
LY3012207Tumor assessments will be performed for each patient at the times shown in Attachm ent 1 until 
docum ented progressi on for patients wi th CR, PR, or SD, and/or for patients who have 
discontinued study  treatm ent due to toxicit y or reasons other than PD.  Imaging requi rements 
include computed tomography ( CT)scan or m agneti c resonance imaging (MRI) of chest, 
abdo men, and pelvis and other areas, as clinically  indicated.  
Com puted tom ography  scans, including spi[INVESTIGATOR_15143], are the preferred methods of measurement.
The exploratory  PET Scan performed pre and post Cycle [ADDRESS_1154018] (wi th IV and oral 
contrast).  A PET scan alo ne or as part of a PET -CT m ay be perform ed for addi tional analyses ,
but cannot be used to assess response according to RECIST .
The m ethod of tum or assessment used at baseline must be used consistently throughout the 
study .  Pati ents will be evaluated for response according to RECIST v1.1 guidelines (Eisenhauer 
et al. 2009), as outlined in Attachm ent 8 .
8.4. Procedure/Sampling Compliance
Every  attem pt will be m ade to enroll patients who have the ability to understand and co mply 
with instructi ons.  Noncom pliant pati ents m ay be disc ontinued fro m the study .
The collection t imes of safet y assessments, PK samples ,and efficacy measurements are given as 
targets to be achieved wit hin reasonable limits.  The scheduled time points may be subject to 
minor al terati ons; however, the actual col lection time must be correctly recorded on the eCRF.
The scheduled co llection times may be modified by [CONTACT_365208] y 
and PK informat ion obtained during the study .  Any  major m odificat ions that might affect the 
conduct of the study , pati ent safet y, and/or data integrit y will be detailed in a protocol 
amendment.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 56
LY30122079.Data Management Methods
9.1. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructional material to the study sites, as appropriate
sponsor start-up training to instruct the invest igators and study  coordinators.  This sessio n 
will give instruction on the protocol, the completion of the CRFs, and study  procedures
make periodic vi sits to the study  site
be available for consultation and stay  in contact [CONTACT_47556], 
telephone, and/or fax
review and evaluate CRF data and/or use standard computer edits to detect errors in data 
collect ion.
conduct a qualit yreview of the database. 
In addit ion, Lilly or its representatives willperiodically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  [CONTACT_82412]/or regulatory  agencies a t any  time. Invest igators will be given notice before 
an audit occurs.
To ensure the safet y of parti cipants in the study , and to ensure accurate, complete, and reliable 
data, the invest igator will keep records of laboratory tests, clinical notes, and pati entmedical 
records in the patient files as original source documents for the study .  If requested, the 
investigator will provide the sponsor, applicable regulatory  agencies, and applicable ERBs /
institutional review board s(IRBs) with direct access to the original  source documents.
9.2. Data Capture S ystems
9.2.1. Case Report Form
An electronic data capture sy stem  will be used in this study .  The si te maintains a separate source 
for the data entered by  [CONTACT_92363] -provided electronic data capture sy stem .
Case report form data will be encoded and stored in a clinical trial database.
For data handled by a data management third-party organization ( TPO ),CRF data and some or 
all data that are related will be managed and stored electronically  in the TPO system .  
Subsequent to the final database lock, validated data will be transferred to the Lilly data 
warehouse, using standard Lilly  file transfer processes .
For data handled by [CONTACT_365210], CRF data and some or all dat a that are related will be 
managed by  [CONTACT_365211]’s system.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 57
LY30122079.2.2. Ancillary Data
Data m anaged by  a central  vendor will  be stored electronically  in the central  laboratory’s 
database system.  Data will subsequent ly be trans ferred from the central vendor to the Lilly
clinical laboratory  resul ts modernizati on (CLRM) system .
Bioanaly tical data will  be stored electronically in the bioanaly tical laboratory ’s database.  Data 
will subsequently be transferred fro m the bioanaly ticallaboratory  tothe Lilly  CLRM system .
Digital ECGs will be electroni cally transmitted to a central ECG laboratory  designated by  [CONTACT_11007] .  
The central ECG laboratory  will perf orm a basic quali ty control  check (for example, 
demographics and study  details) andwill then store the ECGs in a database .  At a future time, the 
stored ECG data may be overread at the central ECG laboratory  for further evaluat ion of 
machine -read measurements or to meet regulatory  requi rements.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint m anagement sy stem .
I5B-MC-JGDM (c)Phase [ADDRESS_1154019] deviat ion, minimum and 
maximum .  Categorical endpo ints will be summarized using the number of pat ients, frequency ,
and percentages. For time- to-event end points, the Kaplan -Meier curves (Kaplan and Meier 
1958) will be est imated, and quartiles and rates at various time po ints together with the 95% CI 
will be provided. Missing data will not be imputed.
The interpretation of the study  resul ts will be the resp onsibili ty of the invest igator with the Lilly
CRP , pharm acokineticist, and statist ician.  The CRP and statist ician will also be responsible for 
the appropriate conduct of an internal review for both the final study  report and any  study -related 
materi al to be authorized by [CONTACT_338289].
Thisstudy  will have [ADDRESS_1154020] -olaratumab m onotherapy  biopsy ,and the predose C2D1 
whole blood draw .
If the patient is nonco mpliant during olaratumab monotherapy  (Cycle 1) and does not undergo 
the pre -treatm ent tissue biopsy, the post -olaratum ab m onotherapy  biopsy ,or the predose C1D1 
and predose C2D1 who le blood draw , he or she will be considered noneval uable and may  be 
replaced.
It is hypothesi zed that 49% (17 out of 35) or more patients will  have a reducti on of  at least 30% 
in PDGFRα level change in tissue from baseline to post-olaratum ab m onotherapy . The sample 
size of 35 patients provides a 95% CI th at the hit rate ( proporti on of  patients wi th at least 30% 
reducti on in PDGFRα level change from baseline) will be between 31% and 66%, which 
excludes a 30% or lower hit rate.  
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 59
LY301220710.1.2. Analysis Populations
Efficacy analysis : the efficacy analysis will be performed on the intent-to-treat ( ITT)populat ion,
which includes all enrolled patients. The ITT populat ion will be included in overall pat ient 
listings, in summary tables of pat ient demographics and disease characterist ics, in the list of 
treatm ent discont inuat ion after enrollment, and in the analysis o f efficacy.
Safety analysis :  all enrolled pat ients who receive any quant ity of IP, regardless of their 
eligibilit y for the study , will be included in the safety  analysis .  Saf ety evaluat ion will be 
perform ed based on the actual therapy  a pati ent has received.
Biomarker analysis : the bio marker evaluable 1 (BE1 ) popul ation will include all ITT patients 
with evaluable samples at both baseline and post -olaratum ab m onotherapy .  The BE1 populat ion 
will be used in the bio marker analyses for the primary  objective and exploratory  object ives. The 
biomarker evaluable 2 (BE2) populat ion will include all ITT populat ion with evaluable samples 
at both baseline and post-combinat ion (olaratum abplus doxorubicin )therapy , and will be used in 
the bio marker analyses for the exploratory  object ives.
10.2. Patient Disposition
All patient discont inuat ions will be documented, and the extent of each pat ient’s participat ion in 
the study  will be reported.  If known, a reason for their discont inuation will be given.
10.3. Patient Charac teristics
Patient characterist ics will include a summary o f the fo llowing:
Patient dem ographics including age, sex, screening height and weight, and screening 
body  mass index will be reported
Baseline disease characterist ics
Historical diagnoses
Pre-exist ing condit ions
Prior disease -related therapi [INVESTIGATOR_014] 
Concomitant medicat ions
Tissue histology  grouped as leiomyosarcom a (LMS )or non -LMS .
Other patient characterist ics will b e summarized as deemed appropriate.
10.4. Safety Analyses
All patients who receive at least [ADDRESS_1154021] ments, and results fro m ECHO/MUGA scans. 
All patients will be assessed regularly  for potenti al occurrence of AEs fro m the time that the 
patient provi des inform ed consent until [ADDRESS_1154022] 1 occurrence of a 
I5B-MC-JGDM (c)Phase [ADDRESS_1154023] severe NCI -CTCAE Versi on 4.0 grade .  
The number of AEs reported per MedDRA preferred term will also be summarized.  Causalit y 
(relationship to study  drug) will be summar ized separately .  Durati on of  AE will  be determined 
and included in list ings alo ng with act ion taken and outcome.
Laboratory  resul ts will be classified according to NCI -CTCAE Versi on 4.0.  Incidence of 
laboratory  abnorm alities will be summarized; laborator y resul ts not corresponding to an NCI -
CTCAE Versi on 4.[ADDRESS_1154024] ics will be provided as appropriate .  Electrocardi ogram  and ECHO/MUGA evaluat ion will 
be listed.
10.5. Biomarker Analyses
Primary analysis :  
All patients in the BE1 populat ion will be evaluated for:
CTC enumerat ion in whole blood  
PDGFR α,PDGFR β, and canonical ligand ( PDGF -A, B, C ,andD) expressio n 
in tum or tissue .  
The percent change fro m baseline for post -olaratumab monotherapy  in biomarker expressio ns 
will be provided for each patient and summarized for all qualified pat ients.  Summary  of number 
and frequency  of patients wi th at least 30% reduction in change fro m baseline PDGFRα 
expressio n will also be provided.  For patients with an observed value o f [ADDRESS_1154025] -olaratumab monotherapy  expressio ns, a value of 0.1 will 
be used. 
10.6. Efficacy
The fo llowing secondary  efficacy endpoints willbe m easured:
Progression -free survival (PFS) :is defined as the time from enrollment until the first 
radiographic documentation of object ive progression as defined by [CONTACT_393] ( v1.1)(Attachment 
8), or death fro m any cause. Patients who die without a reported prior progression will be 
considered to have progressed on the da y of their death. Patients who did not progress or who 
are lost to f ollow -up will be censored at the day  of their last radi ographic tum or assessment .  If 
no baseline or postbaseline radio logic assessment is available, the patient will be censored at the 
date of enrollment .  If death or PD occurs after 2or more consecutive missing radiographic 
visits,censoring will occur at the date of the last radiographic visit prior to the missed visits. The 
useof a new ant icancer therapy or the perform ance of a surgical resect ionprior to the occurrence 
of PD will result in censoring at the date of last radiographic assessment prior to init iation of new 
therapy or surgi cal resecti on.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 61
LY30122073-month PFS :  estimated as the total number of patients who did not progress 3 month s after 
enrollment divided by  [CONTACT_831435].
Overall response rate (ORR): estimated as the total number of CRs, complete responses 
unconfirmed ( CRus), and PRs divided by  [CONTACT_831436].  
Disease control rate (D CR): is comput ed as the total number of pat ients with the best overall 
response of CR, CRu, PR, or SD divided by [CONTACT_126288].  
Rate of Resectability :  is defined as the total  number of patients who are resectable (see 
definit ion of resectabilit y in Section 4) divided by [CONTACT_126288] .
10.7. Pharmacokinetic Analyses
Pharmacokinet ic parameter estimates for olaratumab will be calculated by [CONTACT_831437] [ADDRESS_1154026] had samples collected.  The primary  parameters for analysis will be 
maximum plasma concentration ( Cmax),minimum plasma concentration ( Cmin), 
area under the 
plasma concentration -time curve from time zero to the l ast m easurable pl asma concentration 
(AUC[[ADDRESS_1154027]]), and area under the plasma concentration -time curve from time zero to infinit y
(AUC[0 -∞]) of olaratum ab,where appropriate .  Other noncom partm ental  parameters, such as
half-life ( t1/2), clearance ( CL), and vo lume of distribut ion (V d),may be reported.
Addit ional exploratory  analyses m ay be performed if warranted by  [CONTACT_831438] ( for example , NONMEM) ma y be used if appropriate and approved by [CONTACT_831439].  The versio n of any  software used for the analysis will be documented 
and the program will meet the Lilly requirements of software validat ion.
10.8. Interim Analyses
An interim  analysis will be done to look at the biomarker data once approximately half o f the 
evaluable patients com plete the second tumor tissue biopsy and C2D1 who le blood draw .  The 
purpose of this interim analysis is to review the bio marker and safet y data.  If this interim look at 
the bio marker data warrants any  changes in the study  conduct, i t will  be implemented in an 
appropriate manner ( that is,protocol amendment). Secti on 10.1 describes the 2 database locks 
and the interim analysis that will occur in this study .
I5B-MC-JGDM (c)Phase [ADDRESS_1154028] 
throughout the study  and sharing in a timely manner any  new inf ormation that m ay be rel evant to 
the pati ent’s willingness to continue his or her participat ion in the study  in a timely manner.
The ICFwill be used to explain the potential risks and benefits of study  parti cipat ion to the 
patient in simple terms before the patient is entered into the study  and to document that the 
patient is sat isfied with his or her understanding o f the potential risks and benefits o f 
participat ing in the study and desires to participate in the study.
The invest igator is ult imately responsible for ensuring that informed consent is given by [CONTACT_365215] l egal representati ve before the study  is started.  Thi s includes o btaining the appropriate 
signatures and dates on the ICFprior to the performance o f any protocol procedures and prior to 
the administration o f study  drug .  
In thi s protocol , the term  “informed consent ”includes all consent given by [CONTACT_831440] l 
representatives.
11.2. Ethical Review
Lilly or its representatives must approve all ICFs before they  are used at invest igative sites(s).  
All ICFs must be co mpliant with the ICH guideline on GCP.  
Docum entati on of  ERB approval  of the pro tocol  and the ICF m ust be provi ded to Lilly before the 
study  may begin at the investi gative si te(s).  The ERB(s) will review the protocol as required.
The study  site’s ERBs shoul d be provi ded wi th the fo llowing:
1.the current IB and updates during the course of the study
2. ICF
3.relevant curri cula vi tae
11.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
1) consensus ethics principles derived fro m internati onal ethics gui delines, including the 
Declaration of Helsinki and Council forInternational Organizat ionsofMedical Sciences
(CIOMS ) Internati onal Ethical  Guidelines 
2) the ICH GCP Guideline [E6]
3) applicable laws and re gulat ions.
The invest
igator or designee will prompt ly submi t the protocol  to applicable ERB(s).
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 63
LY3012207Some of the obligat ions of the sponsor will be assigned to a TPO.
An identificat ion code assigned by [CONTACT_831441] e 
patient’s name [CONTACT_65146]’s ident ity when reporting AEs and/or other study -related 
data.
11.3.1. Investigator Information
Site-specific contact [CONTACT_246689] a separate document.
Physicians with a specialt y in onco logy will participate as invest igators in this clinical trial.
11.3.2. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study .  
After reading the protocol, each principal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
11.3.3. Final Report Signature
[CONTACT_831452] , indicat ing agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study . 
The sponsor’s responsible medical o fficer and statistician will appro ve the final clinical study  
report for this study , confi rming that, to the best of his or her knowledge, the report accurately  
describes the conduct and results of the study .
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 64
LY301220712. References
Cockcroft DW, Gault MD. Prediction of creat inine clearance fro m serum creat inine. Nephron . 
1976;16 (1):31-41.
D’Angelo SP, Tap WD, Schwartz GK, Carvajal RD. Sarcoma immunotherapy : past approaches 
and future direct ions[published correction appears in Sarcoma. 2015;2015:259817] . Sarcoma . 
2014;2014:391967.
Dollo ff NG, Russell MR, Lo izos N, Fatatis A .Human bone marrow activates the Akt pathway  in 
metastati c prostate cells through transactivation of the alpha -platel et-derived growth factor 
receptor. Cancer Res . 2007;67(2) :555- 562.
Eisenhauer EA, Therasse P, Bogaerts J, Schwart z LH, Sargent D, Ford R, Dancey J, Arbuck S, 
Gwy ther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Laco mbe D, Verweij J. 
New response evaluat ion criteria in so lid tumours: revised RECIST guideline (versio n 1.1). 
Eur J Cancer . 2009;45(2) 228 -247.
[ESMO] European Societ y for Medical Oncology /European Sarcom a Network Working Group . 
Soft tissue and visceral sarco mas: ESMO Clinical Practice Guidelines for diagnosis, treatment 
and fo llow-up [published correction appears in Ann Oncol . 2015;26(suppl 5):v174- v177] . Ann 
Oncol . 2014;25( suppl 3):iii102 –iii112.
Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon -
Cardo C, Beug H, Grunert S .Autocrine PDGFR signaling promotes mammary cancer 
metastasis. J Clin Invest .2006;116(6 ):[ADDRESS_1154029] E ,Thun MJ. Cancer occurrence. Methods Mol Biol . 2009;
471:3-29.
Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic treatment of so ft-tissue sarco ma -
gold standard and novel therapi[INVESTIGATOR_014]. Nat Rev Clin Oncol .2014;11(4): 187-202.
Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty  B, Rolser R, Malikzay A, Persaud A, Corcoran 
E, Deevi  DS, Bal deres P, Bassi R, Jimenez X, Joynes CJ, Mangalampalli VR, Steiner P, Tonra 
JR, Wu Y, Pereira DS, Zhu Z, Ludwig DL, Hicklin DJ, Bohlen P, Witte L, Ku ssie P. Targeting 
the platel et-derived growth factor receptor alpha wit h a neutralizing human mo nocl
onal 
antibody  inhibits the growth of tumor xenografts: implicat ions as a potential therapeut ic target. 
Mol Cancer Ther . 2005;4(3):369 -379.
[NCIN] National C ancer Intelligence Ne twork. Bone and soft tissue sarco mas [LOCATION_006] incidence and 
survival: 1996 to 2010. Available at: http://www.ncin.org.uk/view?rid=2353. Published 
November 2013. Accessed February  22, 2015.
[NCCN 2011] National Co mprehensive Cancer Network. C linical Pract ice Guidelines in 
Onco logy. Sof t Tissue Sarcom a. V1.2011. Available at :http://www.nccn.org .Accessed 
February  19, 2016.
[NCCN 2014] National Co mprehensive Cancer Network. Clinical Pract ice Guidelines in 
Onco logy. Myel oid Growth Factors. V2.2014. Available at: 
http://williams.medicine.wisc.edu/myelo id_growth.pdf. Accessed February  19, 2016.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 65
LY3012207[NCCN 2016] National Co mprehensive Cancer Network. Clinical Pract ice Guidelines in 
Onco logy.Soft Tissue Sarcom a.V1.2016. Available at : http:// www.nccn.org. Accessed 
February  19, 2016.
Oken MM, Creech RH , Torm ey DC, Horton J , Davis TE, McFadden ET, Carbone PP. Toxi city 
and response criteria of the eastern cooperative oncology  group .Am J Clin Oncol . 
1982;5 (6):649-655.
Park YH, Seo SY, Ha M, Ku JH , Kim HH, Kwak C .Inhibit ion of prostate cancer using RNA 
interference -directed knockdown of pl atelet-derived growth factor receptor. 
Urology .
2011;77(6) :1509.e9 -1509.e 15. 
Russell MR, Jamieson WL, Dollo ff NG, Fatati s A.The α -receptor for platelet -derived growth 
factor as a target for antibody -mediated inhibit ion of skeletal metastases fro m prostate cancer 
cells. Oncogene .
2009;28(3) :412- 421.
Russell MR, Liu Q, Lei H, Kazlauskas A, Fatatis A. The α -receptor for platele t-derived growth 
factor confers bone -metastatic potential to prostate cancer cells by [CONTACT_177735] -and dimerization -
independent mechanisms. Cancer Res . 2010;70(10) :4195 - 4203.
Scho ffski P, Cornillie J, Wozniak A, Lia H, Hompes D. Soft tissue sarco ma: an update on 
systemic treatment options for patients with advanced disease . Oncol Res Treat .
2014;37 (6):355-362.
Shah GD, Loizos N, Youssoufian H, Schwartz JD, Rowinsky EK. Rat ionale for the development 
of IMC -3G3, a fully human immunoglobulin G subclass 1 monoclon al ant ibody  targeting the 
platelet-derived growth factor receptor alpha. Cancer . 2010;116( suppl 4):1018 - 1026.
Sharma S, Taky ar S, Manson SC, Powell S, Penel N. Efficacy and safet y of pharm acological  
intervent ions in second -or later-line treatment of patie nts with advanced so ft tissue sarco ma: a 
systemic review. BMC Cancer . 2013;13:385.
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, 
Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pi[INVESTIGATOR_4607], Schiffer CA, 
Schwartzberg L, Som erfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, 
WolffAC. 2006 update of recommendat ions for the use of white blood cell growth factors: an 
evidence -based clinical pract ice guideline . J Clin Oncol. 2006;24(19):3187 -3205.
Thiery  JP, Acl oque H, Huang RY, Ni eto MA .Epi[INVESTIGATOR_018]-mesenchyma l transi tions in 
development and disease. Cell.2009;139(5) :871 - 890.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 66
LY3012207Attachment 1. Protocol JGDM Study  Schedule
Perform  procedures as indicated in the following tables for the baseline, treatment, and 
posttreatment periods, respectively.  
All screening/baseline evaluations are performed within 14 days prior to enrollment, unless 
otherwi se specified.  Pati ents who m eet all  criteria for enrollment will be assig ned to receive 
treatm ent.  After the patient signs the informed consent form , the si te will register the patient in 
the Interactive Web Response System, which is web- based and accessible 24 hours a day .  
I5B-MC-JGDM (b) Phase  1 Oncology Protocol  Page 67 
LY3012207  Baseline Schedule of Activities  
  Study Period  Baseline   
  Cycle  BL  
  Visit  0  
  Duration  Up to 14 days  
(except where noted)   
  Relative Day from Enrollment  ≤14 ≤7  
Procedure 
Category  Protocol 
Sections  Procedure   Comments  
Study Entry/ 
Enrollment  11.1 Informed Consent  X (within 28 days  
of enrollment ) Written informed consent must be obtained prior to any study -specific screening 
evaluations.  For screening purposes, required assessments pe rformed prior to the 
date of consent may be used provided they are noted exceptions.  
6.1  
[IP_ADDRESS].2.4  Inclusion/Exclusion Evaluation and IWRS   X Patients who meet all criteria for enrollment will be assigned to receive treatment.  
After the patient signs the ICF, the site will register the patient in the IWRS .  
After enrollment, patients should receive their first dose of treatment within 72 
hours (3 days) whenever poss ible. 
Medical 
History  8.1.2  Medical History  X Any preexisting and pretreatment toxicity (treatment - or disease -related) should 
be documented and recorded as part of the pretreatment medical history.  Disease 
characteris tics at initial diagnosis and at study entry will be collected.  
All adverse events must be recorded after signing the informed consent.  
6.1 Demography  X Year  of birth, sex, and race/ethnicity will be collected at baseline.  
6.1 Prior Treatment Therapi[INVESTIGATOR_831418]  X Prior treatment includes any treatment for underlying disease, including 
maintenance therapy.  Start and stop dates should be documented as w ell. 
Physical 
Examination  6.1 Physical Examination   X Physical examination at baseline includes height, weight, and BSA measurement.  
6.1 
Attachment 6  ECOG Performance Status   X Refer to Attachment 6  for details.  
6.1 Vital Signs  X Vital signs include blood pressure, pulse, and temperature.  
Concomitant 
Medications  7.5 Concomitant Medications  X  Concomitant medications will be recorded, including any taken within 30 days 
prior to start of study treatment  (C1D1) . 
 
 
 
Lab/  
Diagnostic 
Tests  
 
 
 
 
 
 
 6.1.[ADDRESS_1154030] to be 
repeated.  Includes a routine UA, and if clinically indicated a microscopic 
analysis.  If routine analysis indicates > 2+ proteinuria, then a [ADDRESS_1154031] demonstrate ≤ 1000 mg of protein in 24 hours.  Testing will 
be performed locally only.  
I5B-MC-JGDM (b)Phase 1 Oncology Protocol Page 68
LY3012207Study Period Baseline
Cycle BL
Visit 0
DurationUp to 14 days
(except where noted)
Relative Day from Enrollment ≤14 ≤7
Procedure 
CategoryProtocol 
SectionsProcedure Comments
Lab/
Diagnostic 
Tests6.1.[ADDRESS_1154032] (women of child -bearing potential only) 
within [ADDRESS_1154033] experienced 
spontaneous amenorrhea for 6 to 12 months.  To be done for women only when 
needed to confirm postmenopausal status.   Testing will be performed locally only.
8.2.3
Tumor Tissue BiopsyX (within 28 days
of enrollment)When submitting a tissue biopsy, sites should examine samples to determine 
adequacy of tumor tissue using their local laboratory procedures prior to first dose 
of olaratumab monotherapy.  If additional tumor biopsies are collected as part of 
clinical care, they should be submitted, along with local pathology reports for 
further analysis (refer to Section 8.2.3 for details).
[IP_ADDRESS]
9.2.2ECG X (within 28 days
of enrollment)A single 12 -lead ECG is to be obtained within 28 days prior to enrollment (refer 
to Section [IP_ADDRESS] andSection 9.2.2 for details) . ECGs will be read locally and 
measurements will be electronically submitted to a central vendor.
[IP_ADDRESS] Echocardiogram or MUGA ScanX (within 28 days
of enrollment)Within 28 days prior to enrollment (refer to Section [IP_ADDRESS] for details) .
[IP_ADDRESS] PET ScanX (within 28 days
of enrollment)Within 28 days prior to enrollment .  PET scans will be read locally by [CONTACT_831442] a central vendor where the images will be stored.
Efficacy
Assessment Attachment 8Imaging Studies (CT/MRI)
Tumor Assessments ( according to RECIST v1.1)X (within 28 days
of enrollment)Within 28 days prior to enrollment (refer to Attachment 8 for details).   CT/MRI 
scans will be read locally and a scan will also be sent for storage at a central 
vendor.
Patient Disposition XAt the time that the patient is discontinued from study participation, information 
regarding the patient status will be collected.
Abbreviations:  β-HCG = beta human chorionic gonadotropin; BL = baseline; BSA = body surface area; C =cycle ; CT= computed tomography; D = day ; 
ECG =electrocardiogram; ECOG =Eastern Cooperative Oncology Group; eCRF = electronic case report form; FSH = follicle -stimulating hormone; ICF=informed consent 
form; IWRS = Interactive Web Response System; MRI = magneti c resonance imaging; MUGA = multi -gated acquisition; PET = positron emission tomography; RECIST = 
Response Evaluation Criteria in Solid Tumors ; UA = urinalysis .
I5B-MC-JGDM (b)Phase 1 Oncology Protocol Page 69
LY3012207On-Study -Treatment Schedule of A ctivities
Study Period Treatment Period
Olaratumab
MonotherapyCombination Therapy
Olaratumab + Doxorubicin
Cycle (21-day cycle 
±3 days)1 2-7
Relative Day within 
Cycle 
(±3 days)1a,b8a1a,b8a
Procedure 
CategoryProtocol 
SectionProcedure Comments
Physical 
Examination6.1 Physical Examination X X X XPhysical examination during treatment period includes weight and BSA 
measurement.  Patients should be weighed on D1 and D8 of each cycle and BSA 
calculated.
6.1
Attachment 6ECOG Performance 
StatusX X Complete prior to treatment infusion .  Refer to Attachment 6 for details.
6.1 Vital S igns X X X XVital signs include blood pressure, pulse, and temperature.
During the Observation Period (initial 2 cycles of olaratumab therapy), collect vital 
signs 3 times:
 within 15 minutes (+5 minutes) prior to olaratumab infusion
 within 1 hour (+5 minutes) after completion of the olaratumab infusion
 within 1 hour (+5 minutes) after completion of the doxorubicin infusion.  
Thereafter (Cycles 3+), obtain vital signs 2 times:  
within 15 minutes (+5 minutes) prior to olaratumab infusion 
within 1 hour (+5 minutes) after completion of the doxorubicin infusion.
Lab/
Diagnostic 
TestsAttachment 2 Hematology X X X XLaboratory assessments may be done within 7 days prior to D1 and D8 of each 
cycle.  See Attachment 2 for details. Testing will be performed locally for patient 
management and centrally for analysis purposes.
Attachment 2
Serum Chemistry X XLaboratory assessments may be done within 7 days prior to D1 of each cycle.  See 
Attachment 2 for details. Testing will be performed locally for patient management 
and centrally for analysis purposes.
Attachment 2Coagulation Profile X XPerform on D1 every other cycle or as clinically indicated.  See Attachment 2 for 
details. Testing will be performed locally only.
Attachment 2 Urinalysis X XLaboratory assessments may be done within 7 days prior to D1 of every other cycle 
or as clinically indicated.  Includes a routine UA, and ,if clinically indicated ,a 
microscopic analysis.  If routine analysis indicates >2+ proteinuria, then a [ADDRESS_1154034] demonstrate ≤[ADDRESS_1154035] on D1 of every cycle or per local practice 
(whichever is of shorter duration).  If a pregnancy test performed on D1 of the cycle 
is positive, confirm with a serum or urine pregnancy test (pregnancy test results are 
not recorded on the eCRF) .  If results are positive, the investigator is to consult with 
the Lilly CRP. Testing will be performed locally only .
8.2.2
Attachment 4PK Samples See Attachment 4 forspecific time points Whole blood samples collected for olaratumab serum PK measurements .
I5B-MC-JGDM (b)Phase 1 Oncology Protocol Page 70
LY3012207Study Period Treatment Period
Olaratumab
MonotherapyCombination Therapy
Olaratumab + Doxorubicin
Cycle (21-day cycle 
±3 days)1 2-7
Relative Day within 
Cycle 
(±3 days)1a,b8a1a,b8a
Procedure 
CategoryProtocol 
SectionProcedure Comments
8.2.5
Attachment 4Immunogenicity 
SamplesSee Attachment 4 for specific time pointsWhole blood samples collected.  If a patient experiences an IRR to olaratumab, 
blood samples for immunogenicity and PK analysis will be taken at the f ollowing 
time points:  (1) as soon as possible after the onset of the IRR, (2) at the resolution 
of the IRR, and (3) 30 (± 3 days) days after onset of the IRR event.
Lab/
Diagnostic 
Tests8.2.4Pharmacogenetic Whole 
Blood Sample for DNA 
storageXWhole blood sample collected.  It is highly recommended to draw the whole blood 
sample prior to the first dose (C1D1 at predose); however, it can be collected later 
during the study if necessary.
8.2.3
Attachment 4Plasma sample for 
exploratory biomarkersXSee Attachment 4 for specific time 
point sPlasma sample collected .  C1D1 at predose, C2D1 (combination therapy pre -dose) 
and at the end of the patient’s study treatment .  See Section [IP_ADDRESS] and Attachment 
4for details and specific time points.
8.2.3
Attachment 4Serum sample for 
exploratory biomarkersXSee Attachment 4 for specific time 
pointsSerum sample collected .  C1D1 at predose, C2D1 (combination therapy pre -dose) 
and at the end of the patient’s study treatment .  See Section [IP_ADDRESS] and Attachment 
4for details and specific time points.
8.2.[ADDRESS_1154036] mandatory peripheral whole blood samples predose at C1D1, C1D8, C2D1, 
C2D8, and C3D1, and at end of the patient’s study treatment or at the time of 
surgical resection.  See Section [IP_ADDRESS] and Attachment [ADDRESS_1154037] dose of 
C2D1. When submitting a specimen from a tumor resection after or during 
combination therapy, sites should examine samples to determine adequacy of tumor 
tissue using their local laboratory procedures.  If additional tumor biopsies are 
collected as part of clini cal care, they should be submitted, along with pathology 
reports, for further analysis .  See Section [IP_ADDRESS] for details.
[IP_ADDRESS] ECG XXTwelve -lead ECGs are to be collected on Day [ADDRESS_1154038] be performed at the end of combination 
therapy Cycles 5 and 7 and when clinically indicated .  After Cycle 7, (resting LVEF 
≥50%), perform echocardiograms or MUGA at the 30 -day follow -up visit.  Patients 
who stop doxorubicin prior to Cycle 7 will undergo the same cardiac monitoring 
assessment. For patients with LVEF <50% or other cardiac dysfunction, perform 
more frequently, if clinically indicated.
[IP_ADDRESS] PET Scan XMandatory PET scan must be collected up to 3days prior to the first dose of C2D1 .  
PET scans will be read locally by [CONTACT_831443] a central vendor where 
the images will be stored.
I5B-MC-JGDM (b)Phase 1 Oncology Protocol Page 71
LY3012207Study Period Treatment Period
Olaratumab
MonotherapyCombination Therapy
Olaratumab + Doxorubicin
Cycle (21-day cycle 
±3 days)1 2-7
Relative Day within 
Cycle 
(± 3 days)1ab8a1a8ab
Procedure 
CategoryProtocol 
SectionProcedure Comments
Efficacy
AssessmentAttachmen t 8Imaging Studies 
(CT/MRI)
Tumor Assessments 
(according to RECIST 
v1.1)XImaging studies and tumor assessments are to be obtained every 6 weeks ( up to 
7days before ), irrespective of treatment cycles as calculated from enrollment, until 
documented progression for patients with CR, PR, or SD, and/or for patients who 
have discontinued study treatment due to toxicity or reasons other than PD.  Refer 
to Attachment [ADDRESS_1154039]/MRI scans will be read locally and a scan will 
also be sent for storage at a central vendor.
Adverse Events 
Collection/
CTCAE 
Grading8.1.[ADDRESS_1154040] dose of all study treatment.
Premedication7.2.2Administer 
premedication prior to 
olaratumab treatment  X X X XPremedicate all patients with the following medications (or equivalent) :  a 
histamine H1 antagonist (eg, diphenhydramine) and dexamethasone intravenously 
30–[ADDRESS_1154041] (eg, 
diphe nhydramine) intravenously 30 -60 minutes prior to each dose of olaratumab. 
7.2.2Administer dexrazoxane 
prior to doxorubicinXDexrazoxane is recommended for all patients receiving 5 or more cycles of 
doxorubicin.
Study 
Treatment7.1.2 Administer olaratumab X X X XAdminister through completion of Cycle 7 or until PD, surgical resection, 
unacceptable toxicity, death, or other withdrawal criteria are met.  
7.1.3 Admin ister doxorubicin XAdministered to all patients during combination therapy for up to a maximum of 6 
cycles (Cycles 2 -7) (unless previous unacceptable toxicity).
Patient Disposition X XAt the time that the patient is discontinued from any component of the study 
treatment or study participation, information regarding the patient status will be 
collected.
I5B-MC-JGDM (b)Phase 1 Oncology Protocol Page 72
LY3012207Abbreviations:  β-HCG = beta human chorionic gonadotropin; AE = adverse event; BSA = body surface area; C = cycle; CR = complete response; CRP = clinical research 
physician; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; D = day ; DNA = deoxyribonucleic acid; ECG =electrocardiogram; 
ECOG = Eastern Cooperative Oncology Group; eCRF = el ectronic case report form; IRR = infusion -related reaction; LVEF = left ventricular ejection fraction; MRI = 
magnetic resonance imaging; MUGA = multi-gated acquisition; PD = progressive disease; PET = positron emission tomography; PK = pharmacokinetic; PR = partial response; 
RECIST = Response Evaluation Criteria in Solid Tumors ; SD = stable disease ; UA = urinalysis .
aStudy  procedures will be performed prior to study drug administration, except where noted (such as vital signs).  In case of dose interrupti on, these evaluations will also be 
done at minimum frequency every 21 days (±3 days).
bRelative day within each cycle ( ≤3 days). Procedure allowed up to 3 days before D1.
I5B-MC-JGDM (b)Phase 1 Oncology Protocol Page 73
LY3012207Posttreatment Discontinuation Follow -Up Schedule of A ctivities
Study Period Posttreatment Discontinuation Follow -Up
Short -Term Follow -Up Long -Term Follow-Up
Visit 801 802-8XX
Duration 30 ±7 days See footnote for duration
Procedure 
CategoryProtocol 
SectionProcedure Comments
Physical 
Examination 6.1 Physical examination X Physical examination will include weight.
6.1
Attachment 6ECOG performance 
statusX Refer to Attachment 6 for details.
6.1 Vital signs X Includes blood pressure, pulse, and temperature.
Lab/
Diagnostic 
TestsAttachment 2 Hematology XSee Attachment 2 for details. Testing will be performed locally for patient 
management and centrally for analysis purposes.
Attachment 2 Serum chemistry XSee Attachment 2 for details .  Testing will be performed locally for patient 
management and centrally for analysis purposes.
Attachment 2 Coagulation profile X See Attachment 2 for details . Testing will be performed locally only.
Attachment 2 Urinalysis XIncludes a routine UA and ,if clinically indicated ,a microscopic analysis.  If 
urine dipstick or routine analysis indicates proteinuria ≥2+, a 24 -hour urine 
collection (to assess protein) must be obtained. Testing will be performed 
locally only .
Attachment [ADDRESS_1154042] (pregnancy test results are not recorded on the 
eCRF).  Additional pregnancy tests may be done after short -term follow -up if 
required by [CONTACT_1295] .  If results are positive, the investigator is to 
consult with the Lilly CRP. Testing will be performed locally only .
[IP_ADDRESS] ECG XTwelve -lead ECGs are to be collected for all patients at the short -term 
follow -up visit. ECGs will be read locally and measurements will be 
electronically submitted to a central vendor.
8.1.3.2Echocardiogram or 
MUGAXEchocardiogram or MUGA scans are to be collected for all patients at the 
short -term follow- up visit. 
Attachment 4 PK sample X See Attachment 4 .
Attachment 4 Immunogenicity sample XSee Attachment 4 .  In addition, if a patient experiences an IRR to olaratumab, 
blood samples for immunogenicity and PK analysis will be taken at the short -
term follow -up after the IRR.
8.2.3
Attachment 4Plasma sample for 
exploratory biomarkersXPlasma sample collected at 30 -day follow -up visit.  See Section 8.2.3 .1for 
details.
8.2.3
Attachment 4Serum sample for 
exploratory biomarkersXSerum sample collected at 30 -day follow -up visit.  See Section [IP_ADDRESS] for 
details.
Efficacy 
AssessmentsAttachment 8Imaging Studies 
(CT/MRI)
Tumor Assessments 
(according to RECIST 
v1.1)X (if applicable) XFor patients who discontinue study treatment ,or complete [ADDRESS_1154043] not progressed , imaging studies and tumor 
assessments are to be obtained every 6 weeks (±7 days) until PD , irrespective 
of treatment cycles, until documented progression as calculated from baseline 
scan.  Patients who have had surgical resection will not be followed for 
subseque nt progression by [CONTACT_20521]. CT/MRI scans will be read 
locally and a scan will also be sent for storage at a central vendor.
I5B-MC-JGDM (b)Phase 1 Oncology Protocol Page 74
LY3012207Study Period Posttreatment Discontinuation Follow -Up
Short -Term Follow -Up Long -Term Follow-Up
Visit 801 802-8XX
Duration 30 ±7 days See footnote for duration
Procedure 
CategoryProtocol 
SectionProcedure Comments
Adverse 
Events 
Collection/
CTCAE 
Grading8.1.[ADDRESS_1154044] possibly related to study treatment will be 
followed until resolution, stabilization, or return to baseline, or until deemed 
irreversible.   After the 30 -day short -term follow- up visit, only new and 
ongoing SAEs deemed related to study treatment will be collected.
Concomitant 
Medication 
Notation7.5Concomitant 
medicationsX
Patient Disposition X XAt the time that the patient is discontinued from study participation, 
information regarding the patient status will be collected.
Abbreviations:  AE = adverse event; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECG = electrocardiogram; ECOG =Eastern 
Cooperative Oncology Group; eCRF = electronic case report form; IRR = infusion -related reaction; MRI = magnetic resonance imaging; MUGA = multi-gated acquisition; PD 
= progressive disease; PK = pharmacokinetic; RECIST = Response Evaluation Criteria in Solid Tumors; SAE =serious adverse event ; UA = urinalysis .
Short -term follow -upbegins the day after the patient and the investigator agree that the patient will no longer continue study treatment and lasts approximately 30 days (±7 days).  
The short -term follow -up visit occurs at or near the end of the short -term follow -up period (± 7 days).
aFollow up for safety :  Patients who undergo surgical resection will be followed for safety for approximately 30 days (±7 days) after surgery.
Long -term follow -upbegins the day after short -term follow up is completed . 
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 75
LY3012207Attachment 2. Protocol JGDM Clinical Laboratory  Tests
All laboratory  screening evaluat ions are to be performed within 14 days prior to enrollment , 
unless otherwise specified.  Eligibilit y for inclusio n in this clinical trial will be based on local 
clinical laboratory  resul ts (not transcribed onto electronic case report forms ); duplicate samples 
will be submitted to the central laboratory .  Treatmen t deci sions m ay be based upon results of 
tests performed locally.  Discrepancies between local and central laboratory that may have an 
impact on eligibilit y or treatm ent deci sions will  not be considered protocol deviat ions.  On -study  
clinical laboratory  tests assay ed for pati ent safet y (such as hematology , serum  chemistry , 
coagul ation, and pregnancy tests) are to be collected prior to study  treatm ent.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 76
LY3012207Clinical Laboratory Tests
Hematologya,bClinical Chemistrya,b
Hemoglobin Serum Concentrations of the following:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Alkaline phosphatase
Leukocytes (WBC) Alanine aminotransferase (ALT)
Neutrophils Aspartate aminotransferase (AST)
Lymphocy tes
Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acid
Platelets Calcium
Glucose, random
Coagulation TestaAlbumin
Prothrombin time (PT) Total protein
Partial Thromboplastin Time (PTT) Chloride
International normalized ratio (INR) Thyroid-stimulating hormone
Direct bilirubin
Urinalysisa,c
Specific gravity
pH Pregnancy testa,e
Protein
Glucose Follicle -stimulating hormone (FSH) a,f
Ketones
Blood
Urine leukocyte esterase
Otherd
Immunogenicity samples
PK samples
Biomarker samples
Abbreviations:  CRP = clinical research physician; D = Day; PK = pharmacokinetics; RBC = red blood cells; WBC 
= white blood cells
aAssay ed by [CONTACT_240260] -designated laboratory.
bDuplicate samples will also be a ssayed by a sponsor -designated laboratory.
cIf urinary  protein is ≥2+ at evaluations, a 24 -hour urine collection (to assess protein) must be collected and must 
be ≤1000 mg of protein in 24 hours (up to 3 business days is allowed if the weekend) .
dAssay ed by a sponsor -designated (central) laboratory.  
eSerum pregnancy test will be performed at screening in females of child -bearing potential only .  Ifthe baseline 
serum test is positive, a repeat serum or urine pregnancy test will be done.  While on-study, a serum or urine 
pregnancy test will be performed in females of child -bearing potential only on D1 of ever y cycle or per local 
practice (whichever is of shorter duration) and at the short-term follow -up visit .  If the pregnancy test performed 
onD1 of each cycle is positive, confirm with a serum or urine pregnancy test.   If results are positive, the 
investigator is to consult with the Lilly CRP.
fPerformed only at screening in menopausal women that have experienced spontaneous amenorrhea for 6 t o 12 
months.  To be done for women only when needed to confirm postmenopausal status.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 77
LY3012207Attachment 3. Protocol JGDM Hepatic Monitoring Tests for 
Treatment -Emergent A bnormality  
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may 
be required in fo llow up with patient s in consultat ion with the Lilly  clinical research physician.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin (HGB)
Hematocrit (HCT) Hepatic Coagulation a
Erythrocy tes (RBC) Prothrombin time (PT)
Leukocytes (WBC) Prothrombin time, INR
Neutrophils b
Lymphocy tes Hepatic Serologies a,c
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets (PLT) Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
Alanine aminotransferase (ALT) Recommended Autoimmune Serology:
Aspartate aminotransferase (AST) Anti- nuclear antibody a
Gamma -glutamyl transferase (GGT) Anti-smooth muscle antibody a
Creatine phosphokinase (CPK) 
Abbreviations:  CRF =case report form; IgG =immunoglobulin G; IgM =immunoglobulin M; INR =international 
normalized ratio; RBC =red blood cells; WBC = white blood cells.
aAssay ed by [CONTACT_11007] -designated laboratory.
bNeutrophils reported by [CONTACT_831444]. Whenever a manual differential is needed to report the neutrophils, the segmented and band forms should 
be added together and recorded on the CRF, unless the CRF specifically provides an entry field f or bands.
cReflex/confirmation dependent on regulatory requirements and/or testing availability.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 78
LY3012207Attachment 4. Protocol JGDM Biomarker, Pharmacokinetic ,
and Immunogenicity Blood Sampling Schedule
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 79
LY3012207Cycle DayDosing
Sampling Time (hour) a Olara PK b IGc,dWhole Blood for 
CTC AnalysesPlasma Serum
Doxorubicin Olaratumab
11Prior to olaratumab infusion f X X X X X
X
Within [ADDRESS_1154045] doxorubicin injection X
2 24 hours ± 3 hours X
5 96 hours ± [ADDRESS_1154046] olaratumab infusion X
9 24 hours ± 3 hours X
10 48 hours ± 3 hours X
12 96 hours ± 3 hours X
18 240 hours ± [ADDRESS_1154047] olaratumab infusion X
5, 7 1 Prior to olaratumab infusion f X X
30-day follow -up Anytime X X XeX X
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 80
LY3012207Abbreviations :  CTC = circulating tumor cells ; IG = immunogenicity ; min = minutes; olara = olaratumab ; PK = pharmacokinetic .
aTime 0 is defined as end of infusion.
bSamples of approximately 3 mL of whole blood will be drawn into tubes.  For the olaratumab samples, olaratumab serum PK measurements will be performed.
cSamples of approximately 4 mL will be collected.
dIn addition to the scheduled immunogenicity samplin g, in the event of an infusion -related reaction, samples are to be collected as close to the onset of the event as possible, at 
the resolution of the event, and 30 days following the event .
eAt end of the patient’s study treatment .
fPretreatment PK samples may be collected up to [ADDRESS_1154048] be collected prior to administering any premedication.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 81
LY3012207Attachment 5. Protocol JGDM Recommendations for 
Reporting Serious Adverse Events
Recommendations for Reporting Serious Adverse Events (SAEs)
When contact[CONTACT_338297] a SAE, pl ease have the fo llowing inform ation available:
Patient Demographics
patient identificat ion (number), sex, date of birth, origin, hei ght, and wei ght
Study Identification
full trial protocol number, invest igator's name, investigator’s number
Study Drug
drug code or drug name, unit dose, total daily dose, frequency, route, start dose, 
cycle details, start date and last dos e date (if applicable)
Adverse Event
descript ion, date of onset, severit y, treatm ent (including hospi[INVESTIGATOR_3094]), acti on 
taken wi th respect to study  drug, clinical significance, test and procedure results 
(if applicable)
Relationship to Study Drug & Prot ocol Procedures
Concomitant Drug Therapy
indicat ion, total  daily dose, duration of treatment, start date, action taken
In Case of Death
cause, autopsy  finding (if available), date, relat ionship to study  drug and protocol 
procedures.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 82
LY3012207Attachment 6. Protocol JGDM ECOG Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status
Activity Status Description
0 Fully active, able to carry on all pre -disease performance without 
restriction
1 Restricted in phy sically  strenuous activity butambulatory and able 
to carry  out performance of a light or sedentary nature , for example,
light housework, office work
2 Ambulato ry and capable of all selfcare but unable to carry out any 
work activities.  Up and about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than 
50% of waking hours
4 Completely disabled.  Cannot carry on any selfcare.  Totally 
confined to bed or chair
5 Dead
Source:  Oken et al. 1982.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 83
LY3012207Attachment 7. Protocol JGDM Creatinine Clearance Formula
Note:   This formula is to be used for calculat ing creatinine clearance ( CrCl )from local 
laboratory results only.  
For serum creatinine 
concentration in mg/dL:
CrCl = (140 – agea) (wt)    0.85 (if female) , or1.0 (if male)
(mL/min) 72serum creatinine (mg/dL )
For serum creatinine concentration in mol/L:
CrCl   = (140 – age a) (wt)  0.85 (if female) , or1.0 (if male)
(mL/min) 0.81serum creatinine 
(mol/L )
aage in years, weight (wt) in kilograms.
Reference:  Cockcroft and Gault 1976.
I5B-MC-JGDM (c)Phase [ADDRESS_1154049] Criteria
Response and progression will be evaluated in this study  using the international criteria proposed 
by [CONTACT_92378] (RECIST): Revised RECIST 
Guideline (versi on 1.1; Eisenhauer et al. 2009).  
Measurability of Tumor at Baseline
Tumor lesi ons/lymph nodes will be categorized at baseline as measurable or nonmeasurable.  
Measurable disease is defined by  [CONTACT_92379] l east 1 m easurable l esion.
Measurable 
Tumor lesi ons:  Measured in at least 1 dimensio n (longest di amet er in the plane o f measurement 
is to be recorded) with a minimum size of:
10 mm by  [CONTACT_92380]  (CT) or m agnet ic resonance imaging (MRI) 
scan (slice thickness 5 mm) 
10 mm caliper measurement by  [CONTACT_40133] (non -measurable lesio ns if cannot 
be accurately measured with calipers)
[ADDRESS_1154050] X -ray.
Malignant lymph nodes:  To be considered pathologically enlarged and measurable, a lymph 
node m ust be [ADDRESS_1154051] scan (CT scan thickness recommended 
to be 5 mm ).
Nonmeasu rable 
All other lesio ns, including small lesio ns (lo ngest di ameter <10 mm or pathological lymph nodes 
with 10 to <15 mm short axis) as well as truly nonmeasurable lesio ns.  Lesio ns considered truly  
non-measurable include:  leptomeningeal disease, ascites , pleural/pericardial effusio ns, 
lymphangitis cut is/pulmo nis,  inflammatory  breast di sease, lymphangit is involvement of skin or 
lung, abdo minal masses/abdo minal organo megaly ident ified by [CONTACT_831445].
Special Considerations for Lesion Measurability
Bone l esions:  
Bone scan, PET scan or plain films are not consi dered adequate imaging 
techniques to measure bone lesio ns.
Lytic bone lesio ns or mixed ly tic-blastic l esions, wit h ident ifiable so ft tissue 
components, that can be evaluated by  [CONTACT_240263], can be considered measurable lesio ns if the so ft tissue com ponent 
meets the definit ion of measurabilit y.
Blastic bone l esions are non -measurable.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 85
LY3012207Cystic lesions:  
Simple cysts should not be considered as malignant lesio ns (neither measurable 
nor nonm easurable) 
Cystic lesions thought to represent cystic metastases can be considered as 
measurable lesio ns, if they meet the definit ion of measurabilit y.  If noncys tic 
lesions are presented in the same patients, these are preferred for select ion as 
target lesio ns.
Lesio ns wi th Prior Local Treatm ent:
Tumor lesi ons situated at a previ ously i rradiated area, or i n an area subjected 
to other loco -regional therapy, are non -measurable unless there has been 
demonstrated progression in the lesio n.  
Baseline Documentation of Target and Non -Target Lesion
Target Lesions
When more than 1 measurable lesio n is present at baseline, all lesions up to a maximum o f 5 
lesions total  (and a m aximum  of 2 lesio ns per organ) representative o f all invo lved organs should 
be ident ified as target lesio ns and will be recorded and measured at baseline. Non-nodal Target 
lesions shoul d be selected on the basis o f their size (l esions with the l ongest di ameter), be 
representative of all invo lved organs, and can be reproduced in repeated measurements..  
Measurable lymph nodes are target lesio ns if they meet the criteria of a short axis of [ADDRESS_1154052] form  (CRF) in millimeters (or 
decimal fract ions of centimeters [cm]).
Nontarget Lesions
All other lesio ns (or sites of disease) are ident ified as nontarget lesio ns(chosen based on their 
representativeness o f involved organs and the ability to be reproduced in repeated measurements) 
and should be recorded at baseline.  Measurement of these lesio ns are not required but should be 
followed as ‘present,’ ‘absent,’ or in rare cases ‘unequivocal progression.’  In addit ion, it is 
possible to record mult iple nontarget lesio ns involving the same organ as a single item on the 
CRF (for example, mult iple liver m etastases recorded as one liver lesio n).
Lymph nodes with short axis 10 mm  but <[ADDRESS_1154053] a short axis <10 mm are considered nonpathological and are not recorded or 
followed.
Specifications by [CONTACT_92383], using a ruler or calipers if clinically 
assessed.  All baseline evaluat ions should be performed as closely as possible to the beginning of 
treatm ent and never more than 4 weeks before the beginning of the treatment.
The same method of assessment and the s ame technique should be used to characterize each 
ident ified and reported lesio n at baseline and during fo llow-up.  Im aging- based evaluat ion is 
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 86
LY3012207shoul d always be done rather than clinical examination unless the lesio n(s) being fo llowed 
cannot be imaged but are assessed by [CONTACT_461].  
An adequate vo lume of a suitable contrast agent should be given so that the metastases are 
demonstrated to best effect and a consistent method is used on subsequent examinat ions for any  
given pat ient.  If prior to enrollmen t it is known a patient is not able to undergo CT scans with IV 
contrast due to allergy  or renal  insufficiency , the decisi on as to whether a non -contrast CT or 
MRI (wi th or wi thout IV contrast) should be used to evaluate the patient at baseline and follow -
up shoul d be guided by  [CONTACT_240265].
Clinical Lesions:  Clinical lesio ns will only be considered measurable when they  are superficial  
and 10 mm diameter as assessed using calipers (for exampl e, skin nodul es).  For the case of 
skin lesio ns, docum entati on by [CONTACT_92385] , incl uding a rul er to estimate the size of the 
lesion is recommended.  When lesio ns can be evaluated by [CONTACT_51752], 
imaging evaluat ion should be underta ken since it is more object ive and may be reviewed at the 
end of the study .
Chest X -ray:  Chest CT is preferred over chest X -ray when progressi on is an important endpoint.  
Lesio ns on chest X -ray may be considered m easurable if they  are cl early  defined and surrounded 
by [CONTACT_92387] l ung.
CT and MRI :  CT scan is the best currently available and reproducible method to measure lesio ns 
selected for response assessment.  Measurabilit y of lesio ns on CT scan is based on the 
assumpt ion that CT slice thickness is [ADDRESS_1154054] slice thickness >5 mm, the 
minimum size for a measurable lesio n shoul d be twi ce the slice thickness.  MRI is also 
acceptable in certain situations (for example, for body  scans).  If there is concern about radiat ion 
exposure at CT, MRI m ay be used instead of CT in selected instances.  
Ultrasound:   Ultrasound should not be used to measure lesion size.  Ultrasound examinat ions 
cannot be reproduced in their ent irety for independent review at a later date and, because they are 
operator depen dent, i t cannot be guaranteed that the same technique and measurements will be 
taken fro m one assessment to the next.  If new lesions are identified by  [CONTACT_92388] , confi rmation by [CONTACT_462] i s advised.
Endoscopy, Laparoscopy :  Th e utilizat ion of these techniques for object ive tumor evaluat ion is 
not advised.  However, such techniques can be useful to confirm co mplete pathol ogical response 
when biopsies are obtained or to determine relapse in trials where recurrence fo llowing com plete 
response or surgical resect ion is an endpo int.
Tumor Markers :  Tum or markers al one cannot be used to assess tumor response.  If markers are 
initially above the upper normal limit, they  must norm alize for a patient to be considered in 
complete response (CR).  Specific guidelines for both prostate -specific ant igen (P SA) response 
(in recurrent prostate cancer) and CA -125 response (in recurrent ovarian cancer) have been 
published .  
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 87
LY3012207Cytology, Histology :  These techniques can be used to different iate between partial responses 
(PR) and complete response (CR) in rare cases if required by [CONTACT_990] (for example, residual 
lesions in tum or types such as germ cell tumors, where known residual benign tumors can 
remain).  When effusio ns are known to be a potential adverse effect of treatment (for example, 
with certain taxane co mpounds or angiogenesis inhibitors), the cy tological confirmat ion of the 
neopl astic ori gin o f any effusio n that appears or worsens during treatment can be considered if 
the measurable tumor has met criteria for response or stable disease (SD) in order to diff erent iate 
between response (or SD) and progressive disease (PD). 
Pet Scan (FDG -PET, PET CT) :  PET is not recommended for lesio n assessment. If a new lesio n 
is found by  [CONTACT_10052], another assessment must be done by  [CONTACT_4654], unless the PET CT i s of diagnostic 
qualit y.  If CT is done to confirm the results of the earlier PET scan, the date of progression must 
be reported as the earlier date of the PET scan. 
Bone Scan :  If lesions measured by [CONTACT_92390], it is necessary to repeat 
the bone scan when trying to ident ify a complete response (CR) or partial response (PR) in target 
disease or when progression in bone is suspected. 
Response Criteria
Evaluation of Target Lesions 
Complete Response (CR):   Disappearance o f all target lesio ns.  Any patholo gical  lymph nodes 
(whether target or non -target) m ust have reduct ion in short axi s to <[ADDRESS_1154055] norm alized.
Partial Response (PR):   At least a 30% decrease in the sum o f diameter of target l esions, taking 
as reference the baseline sum diameters.
Progressive Disease (PD):   At least a 20% increase in the sum of the diameters of target lesio ns, 
taking as reference the smallest sum on study  (including the baseline sum if that is the smallest).  
In addit ion to the relat ive increase of 20%, the sum must also demonstrate an abso lute increase 
of at least 5 mm.   The appearance of one or more new lesio ns is also considered progression.
For equivocal findings of progression (for example, very  small  and uncertain new l esions; cyst ic 
changes or necrosi s in exist ing lesions), treatment may cont inue unt il the next scheduled 
assessment.  If at the next scheduled assessment, progression is confirmed, the date of 
progression should be the earlier date when progressio n was suspected.
Stable Disease (SD):   Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify  for PD, taking as reference the smallest sum diameters while on study .
Not Evaluable:  When an inco mplete radio logic assessment of target lesio ns is performed or 
there is a change in the method of measurement from baseline that impact sthe abilit y to make a 
reliable evaluat ion of response . 
Evaluation of Nontarget Lesions
Complete Response:   Disappearance of all nontarget lesio ns and normalizat ion of tum or marker 
level.  All lymph nodes must be non -pathol ogical or norm al in size (<10mm short axis).
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 88
LY3012207Non-CR/ non -PD:  Persistence of 1 or more nontarget lesio ns and/or maintenance of tumor 
marker l evel above the norm al limits.
Progressive Disease:  Unequivocal progressi on of  exist ing nontarget lesio ns.  The appearance o f 
1 or m ore new l esions i s also consi dered progression.
Not Evaluable : When a change in method of measurement from baseline occurs and impacts the 
abilit y to make a reliable evaluat ion of response .
Evaluation of Best Overall Response
The best overall response is the best response recorded fro m the start of the study  treatment until 
the earliest of object ive progression or start of new anticancer therapy, taking into accoun t any  
requi rement for conf irmation.  The patient’s best overall response assignment will depend on the 
findings of both target and nontarget disease and will also take into considerat ion the appearance 
of new lesio ns.  The Best Overall Response will be calculated via an algorithm u sing the 
assessment responses provided by  [CONTACT_92391] .  
Time Point Response
It is assumed that at each protocol -specified t ime point, a response assessment occurs.  ( When no 
imaging/measurement is done at all at a particular time point, the patient is not evaluable (NE) at 
that time po int.)  Table [ADDRESS_1154056] measurable disease at baseline.
Table 1. Time Point Response: Patients with Target ( Nontarget) Disease
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/no n-PD No PR
CR Not evaluated No PR
PR Non-PD or not all evaluated No PR
SD Non-PD or not all evaluated No SD
Not all evaluated Non-PD No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
Abbreviations:  CR = complete response; PR = partial response; SD = stable disease.; PD = progressive disease; NE 
= inevaluable. 
Table [ADDRESS_1154057] nonmeasurable disease only .
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 89
LY3012207Table 2. Time Point Response: Patients with Nontarget Disease Only
Nontarget Lesions New Lesions Overall Response
CR No CR
Non-CR/no n-PD No Non-CR/no n-PDa
Not all evaluated No NE
Unequivocal PD Yes or No PD
Any Yes PD
Abbreviations:  CR = complete response; PD = progressive disease ; NE = inevaluable.
anon-CR/non -PD is preferred over SD for nontarget disease. 
Frequency of Tumor Re -Evaluation
A baseline tumor evaluat ion must be perform ed within [ADDRESS_1154058] therapy  is not known, fo llow-up every  6-8 weeks is 
reasonable.  Normally , all target and non -target si tes are evaluated at each assessment using the 
same m ethod.  However, bone scans may need to be repeated only when CR is ident ified in 
target disease or when progression in bone is suspected.  
Confirmatory Measurement/Duration of Response
Confirmation :
The m ain goal  of confirmat ion of object ive response in clinical trials is to avoid overest imating 
the response rate observed .  The confir mation of response is particularly important in 
nonrandomized trials where response (CR/PR) is the primary  end point.  In this setting, to be 
assigned a status of PR/CR, changes in tumor measurements must be confirmed by [CONTACT_831446] p erformed no l ess than [ADDRESS_1154059] occur; assessment of 
nontargets is not required.  
However, in randomized trial (Phase 2 or 3) or studies where SD or progression is the primary 
endpo ints, confirmat ion of res ponse is not required.  But, eliminat ion of the requirement may  
increase the importance of central review to protect against bias, in particular of studies which 
are not blinded.
In the case of SD, fo llow-up m easurements m ust have met the SD criteria at le ast once after start 
of treatm ent at a minimum interval not less than [ADDRESS_1154060] met for 
CR or PR (whichever is first recorded) until the first date that disease is recurrent or object ive 
progression is observed (taking as reference for PD the smallest measurements recorded on 
study ).
I5B-MC-JGDM (c)Phase [ADDRESS_1154061] ively documented.
Duration of Stable Disease
Stabl e disease is m easured from  the start of the treatment (in rando mized trials, from date of 
rando mizat ion) unt il the criteria for objective progressio n are m et, taking as reference the 
smallest sum on study  (if the baseline sum is the smallest, that is the reference for cal culat ion of 
PD).  
Independent Review of Response and Progression
When object ive response (CR + PR) is the primary end point, and when key drug development 
decisio ns are based on the observat ion of a minimum number of responders, it is recommended 
that all claimed responses be reviewed by [CONTACT_13461](s) independent of the study .  If the study  is a 
rando mized trial, ideally reviewers should be blinded to treatment assignment.  
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 91
LY3012207Attachment 9. Protocol JGDM CYP3A4, CYP2D6, and P -gp 
Inhibitors and Inducers of Doxorubicin
CYP3A4 Inducers Strong CYP3A4 Inhibitors Moderate CYP3A4 Inhibitors
Aminoglutethimide Clarithromycin Amiodarone
Bosentan Chloramphenicol Amprenavir
Carbamazepi[INVESTIGATOR_831419] (in liver only) Conivaptan Atazanavir
Fosphenytoin Cremophor EL Cimetidine
Nafcillin Cyclosporine Ciprofloxacin
Nevirapi[INVESTIGATOR_831420] , starfruit, and Seville oranges Efavirenz
Rifampin Indinavir Erythromycin
Rifapentine Indinavir and ritonavir FK1706
St. John's wort Itraconazole Fluconazole 
Ketoconazole Fluvoxamine
Lopi[INVESTIGATOR_831421] 
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 92
LY3012207CYP2D6 Inducers CYP2D6 Inhibitors P-glycoprotein 1 (P -gp) Inhibitors
Rifampin Amiodarone Amiodarone
Celecoxib Azithromycin
Chloroquine Captopril
Chlorpromazine Clarithromycin
Cimetidine Cyclosporine
Citalopram Pi[INVESTIGATOR_831422] (high dose)
Fluoxetine
Fluphenazine
Fluvoxamine
Haloperidol
Labetalol
Lobeline
Lomustine
Methadone
Mibefradil
Moclobemide
Nortuloxeline
Paroxetine
Perphenazine
Propafenone
Quinacrine
Quinidine
Ranitidine (ranitidine, Zantac)
Risperidone (weak)
Ritonavir
Serindole
Sertraline (weak)
Thioridazine
Valproic acid
Venlafaxine (weak)
Vinblastine
Vincristine
Vinorelbine
Yohimbine
Abbreviation: CYP = cytochrome P450.
aAprepi[INVESTIGATOR_831423]-emetic is recommended.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 93
LY3012207Attachment 10. Protocol JGDM Protocol A mendment I5B-
MC-JGDM (c) Summary : A Phase 1b Trial to A ssess the 
Modulation of Biological Markers in Patients with 
Potentially  Resectable Soft Tissue Sarcoma Treated with 
Olaratumab Monotherapy  Followed by  [CONTACT_831447]  I5B-MC-JGDM, A Phase 1b Trial to Assess the Modulation o f Biological Markers in 
Patients wi th Potenti ally Resectable Soft Ti ssue Sarcom a Treated wi th Olaratum ab Monotherapy  
Followed by [CONTACT_831448], has been amended.  The new 
protoco l is indicated by  [CONTACT_11827] ( c) and will be used to conduct the study  in place of any 
preceding versio n of the protocol.
The overall changes and rationale for the changes made to this protocol are as fo llows:
The term  QTcF was defined in the abbreviat ions and definit ion sect ion.
Fridericia’s QT correcti on formulawas added for pati ents wi th bundle branch blo ck.
Exclusio n criteria 22 was updated by  [CONTACT_831449]’s 
abilit y to adhere to the protocol and to indicate the exclusio n criteria refers to a 
concomitant systemic disorder the pati ent is currently  experi encing.
Exclusio n criteria 23 was corrected.
Secti on 7.1.2. was updated to r eference the Pharmacy Manual rather than text from 
the manual. 
A clarificat ion was made in Sect ion [IP_ADDRESS] for dose del ays that collection o f PK 
samples should be derived fro m time theactual olaratumabdose was given vs when 
dose was originally  expected .
Secti on [IP_ADDRESS]. was corrected for tumor tissue from any  posttherapy  surgical 
resection to be opti onal rather than required .
Secti on 10.1. and 10.1.1. was clarified to add the C1D1 predose blood draw to the 
definit ion of an evaluable pat ient.
A clarificat ion was made in the schedule o f events to both treatment and baseline PET 
scan to move them  to the appropri ate pl ace in the schedule .
A change was made in the t iming of pre -Dose PK sample in order to allow for 
samples to be collected before pre-medications are administered. 
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 94
LY3012207Revised Protocol Sections
Note: Deletions have been ident ified by [CONTACT_58001] .
Addit ions have been identified by  [CONTACT_58002] .
Where exist ing language is underlined, addit ions have been ident ified by [CONTACT_831450] e underscore .
4. Abbreviations and Definitions
QTcF Fridericia’s QT corrected interval
6.1.2. Exclusion Criteria
[9] Have adequate hematologic, organ, coagulat ion, and cardiac funct ion within 
2weeks (14 days) prior to enrollment:
• Absolute neutrophil count (ANC) ≥1.5 x 109/L.  Granulocyte co lony-
stimulat ing factor (G -CSF) cannot be administered within 2 weeks 
(14days) prior to enrollment.
• Platelet coun t ≥100 x 109/L.
• Hem oglobin ≥9.0 g/dL.  No transfusio ns are allowed within 2 weeks 
(14days) prior to enrollment.
• Creatinine clearance ≥45 mL/min (refer to Attachment 7 for the 
Cockcroft -Gaul t formula).
• Proteinuria ≤1000 mg in 24 hours (if routine urinalysis indicates 
≥2+proteinuria).
• Total  bilirubin bel ow upper limi t of normal (ULN) (except for patients 
with Gilbert’s Syndro me, who must have a total bilirubin <3 mg/dL).
• Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) 
≤3.0 × ULN; if the liver has tumor invo lvement, AST and ALT ≤5.0 × 
ULN are acceptable.
An adequate coagulat ion function as defined by [CONTACT_240212] ≤1.[ADDRESS_1154062] or prothrombin t ime ≤1.[ADDRESS_1154063] in time 
≤1.[ADDRESS_1154064] no history  of active bleeding 
(defined as within [ADDRESS_1154065] dose of study  drug) or pathological 
condi tion that carries a high risk of bleeding (for example, tumor 
involving m ajor vessels or known esophageal varice s).
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 95
LY3012207[19] Have a Bazett’s corrected QT interval of >450 msec for males and >470 msec 
for females on screening ECG utilizing Bazett’s correction. For bundle branch 
block pat ients, have a QTcF interval o f >450 m sec for males and > 470 m sec for 
females on screening electrocardiogram (ECG) utilizing Fridericia’s correction.
[22]Have a serious pre-exist ing m edical condit ions that in the opi[INVESTIGATOR_3078] n of the 
investigator would exclude the patient as a candidate for this study .concomi tant 
systemic disorder (for example, act ive infect ion including human 
immunodeficiency  virus, or cardiac disease) that , in the opi[INVESTIGATOR_3078] n of the 
investigator, would co mpromise the patient’s abilit y to adhere to the 
protocol .[23] Have a known allergy to any  of the t reatment components 
including a history  of allergi c react ions attributed to compounds of chemical or 
biological  com position similar to ol aratum abintravenous (IV) inject ion on Day  
1. 
6.2 Summary of Study Design
Long -term follow- up:  begins the day  after short- term follow-up is 
completed.
Follow-up for progression -Patients who discont inue study  
treatm ent, or have co mpleted [ADDRESS_1154066] not init iated a new systemic 
treatm ent for thei r disease will be ass essed for progressio n by 
[CONTACT_334863]  6 weeks ( ±<7 days) until PD.  Patients who 
have had surgical resect ion will not be fo llowed for subsequent 
progression by  [CONTACT_831451].
7.1.2. Olaratumab
Please refer to the Pharmacy  Manual for information on preparing the olaratumab dosing 
solution for infusio n.
Prepared Olaratumab Dosing Solut ion for Infusio n:  Chemical and physical in -use stabili ty for 
the prepared olaratumab dosing solut ion has been dem onstrated for up to 24 hours below 25ºC 
(77ºF) in the concentration range of 1.2 mg/mL to 6.4 mg/mL.  It is recommended that the 
prepared dosing so lution be used immediately to minimize the risk of microbial contaminat ion.  
If not used immediately, the prepared olaratumab dosing so lution must be stored un der 
refrigerat ion at 2ºC -8ºC (36ºF -46ºF) for a duration not to exceed 24 hours.  If the prepared 
solution is held at room temperature (below 25ºC [77ºF]), it must be used within 4 hours.  Do not 
freeze and/or shake prepared olaratumab dosing solut ion for infusio n.
Asept ic technique is to be used when preparing and handling o laratumab.  Patients are to receive 
a loading dose of 20 mg/kg on Day s [ADDRESS_1154067] cy cle of co mbinat ion therapy  (Cycl e 2), followed by  15 mg/kg of ol aratum ab 
on Day s 1 and 8 of each subsequent 21- day treatment cycle (Cycle 3 -Cycle 7), administered as 
an IV infusio n.  On the day s that both olaratumab and doxorubicin are administered, olaratumab 
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 96
LY3012207will be administered prior to doxorubicin.  The dose of olaratumab is dependent upon the 
patient’s body  weight (Secti on 7.3.1).  Actual  body weight will  be used for dose calculation.  
Subsequent doses of olaratumab must be recalculated if there is a ≥10% change (increase or 
decrease ) in body  weight; subsequent doses may  be recal culated if there is a <10% change in 
body  weight from  prior dose and considered clinically  relevant by  [CONTACT_12707].
Olaratum ab is com patible wi th commo nly used infusion containers.  Refer to the IB or pharmacy 
manual for detailed informat ion.  Ol aratumab concentrati on of  below 1.2 m g/ml in prepared dose 
shoul d be avoi ded due to dilut ion of excipi[INVESTIGATOR_840], which are important in maintaining stabilit y.
The dose of olaratumab will be aseptically  withdraw n from the vial and transferred to a sterile 
infusio n bag or an evacuated glass container.  To prepare the dose, a sufficient quantit y of sterile 
norm al saline (0.9% wei ght/vol ume) sol ution should be added (or removed in the case of a 
prefilled container s uch as AVIVA) to make the total vo lume 250 mL.  The container should be 
gently inverted to ensure adequate mixing.  In some cases, the vo lume of infusio n solution 
requi red m ay exceed the 250- mL scenario described here to keep the infusio n solution 
concentr ation within the desired range stated above.  This situation may  be m ore likely with the 
requi red loading dose of 20 mg/kg given in Cycle 1, but may also apply to any  subsequent cycle 
depending on the patient’s body weight.  In case of dose volumes >250 mL , an em pty 500-mL 
container of acceptable material o f constructi on can be used without addition o f any normal 
saline.  A pre -filled container (filled with 0.9% normal saline) of >250 m L size can be used as 
long as the material o f constructi on is acceptable and the concentration of olaratumab in prepared 
dose remains wi thin 1.2 mg/mL to 6.4 mg/mL.
The dose should be infused over approximately  60 minutes.  The infusio n rate shoul d not exceed 
25 m g/min.  Infusio n durations longer than 60 minutes are permitted in specific circumstances 
(that i s, for pati ents wi th higher body  weight f or who m the upper limit of infusio n rate i s limi ted 
or in the setting o f prior olaratumab Grade 1 -2 infusion -related reacti on [IRR]); the infusio n 
durati on m ust al ways be accurately recorded.
The infusio n set m ust be flushed immediately  postinfusi on of dose wi th sterile normal saline to 
ensure complete delivery  of the cal culated dose.
7.2.1. Treatments Administered
Table JGDM 1 Treatment Regimens
Treatment Cycle
Length
(Days)Study Drug Dose Timing Route 
Monotherapy 
Cycle 121 Olaratumaba20 mg/kg approximately 1 hour 
infusion D1, D8 IV
1-hour ( +5 minutes) 
Observation Periodb

I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 97
LY3012207Combination Therapy
Cycle 221 Olaratumaba20 mg/kg approximately 1 hour 
infusion D1, D8 IV
1-hour ( +5 minutes) 
Observation Periodb
followed by
[CONTACT_240219]75 mg/m2IV injection on D1 IV
Combination Therapy
Cycle 3 –Cycle 721 Olaratumaba15 mg/kg approximately 1 hour 
infusion D1, D8 IV
Doxorubicinc75 mg/m2IV injection on D1 IV
Abbreviations:  D =day; eCRF = electronic case report form; IRR = infusion -related reaction; IV = intravenous; 
PO= orally.
aPremedicate all patients with the following (or equivalent) medications:  a histamine H1 antagonist (for example, 
diphenhydramine ) and dexamethasone intravenously 30 –[ADDRESS_1154068] (for example, 
diphenhydramine) intravenously 30 -
60 minutes prior to ea ch dose of olaratumab.  Additional premedication may 
be provided at the investigator’s discretion.  Premedication must be provided in the setting of a prior Grade 1-2 
IRR, as detailed in Section
 7.2.2 and Section [IP_ADDRESS].1.[ADDRESS_1154069] be adequately 
documented in the eCRF.
bA 1-hour (+5 minutes) Observation Period is required after the administration of the initial [ADDRESS_1154070] vital signs 3 times:  1) within 15 minutes (+5 minutes) prior 
to olaratumab infusion, 2) within 1 hour (+5 minutes) after completion of the olaratumab infusion, and 3) within 
1 hour (+5 minutes) after completion of the doxorubicin infusion.  If no evidence of an IRR manifests during the 
initial 2 cycles of olaratumab, then no observation period is required for subsequent treatment cycles.  In the 
event an IRR occurs thereafter, then the 1 -hour Observation Period should be reinstituted; see Section 7.1.2 .  
Thereafter (Cycles 3+), obtain vital signs 2 times:  1) within 15 minutes (+5 minutes) prior to olaratuma b 
infusion and 2) within 1 hour (+5 minutes) after completion of the doxorubicin infusion.
cAdminister doxorubicin according to institutional guidelines and/or clinical practice as an IV injection or as an 
infusion in less than within 60 minutes.  Decrease the rate of doxorubicin administration if erythematous streaking 
along the vein proximal to the site of infusion or facial flushing occurs.  Infusion or injection start and end times 
will need to be recorded.  Starting with Cycle 2, dexrazoxane may be administered at a 10:1 ratio 
(dexrazoxane:doxorubicin) at the investigator’s discretion according to instructions provided in the pharmacy 
manual for this study, beginning within 30 minutes prior to the doxorubicin infusion for prevention of 
cardiotoxicity.  It is recommended that all patients receiving 5 or more cycles of doxorubicin receive 
dexrazoxane.
[IP_ADDRESS]. Dose Delays, Modifications, and Discontinuations
To begin dosing at each cy cle, the foll owing cri teria m ust be fulfilled:After treatment has been 
initiated, in order to start the next cycle the fo llowing cri teria must be f ulfilled:
ANC ≥1.0 × 103/L (1000/ L; ≥1.0 × 109/L)
I5B-MC-JGDM (c)Phase [ADDRESS_1154071] 
be 750/L; 0.75 × 109/L.  If the ANC is 750/L, the Day  8 administrati on 
of olaratum ab may  be delayed for a m aximum  of 7 day s.  If the ANC level has 
not increased to 750/L within 7 days, then the Day 8 olaratumab dose in 
that cy cle shoul d be skipped and dosing resumed on Day  1 of the f ollowing 
cy
cle if cri teria f or dosing are met.  If all dosing criteria are met, a delay  or 
omissio n of the Day  8 olaratum ab dose shoul d not resul t in a delay  of the 
Day 1 olaratum ab dose of the fo llowing cycle. 
Platelets ≥100 × 103/L (100,000/ L; ≥100 × 109/L)
Hem oglobin ≥98g/dL
Creatinine clearance ≥45 mL/min (refer to Attachment 7 for the 
Cockcroft -Gaul t formula)
Proteinuria ≤1000 m g in 24 hours (if routi ne urinalysis indicates 
≥2+proteinuria) (to be performed every other cy cle)
Total  bilirubin bel ow ULN
AST and ALT ≤3.[ADDRESS_1154072], or ≤[ADDRESS_1154073] if the transaminase elevat ion is due 
to liver metastases
Olaratum ab-related AEs that ar e NCI-CTCAE Version 4.0 Grade <2 or 
equivalen t severit y to baseline
Delays:
In general, dose delays of 1 study  drug (ol aratum ab or doxorubi cin) due to toxi city guidances 
outlined in Sect ions [IP_ADDRESS].1 and [IP_ADDRESS].2 will not necessitate delays of the other study drug.
Treatment may be delayed for up to 21 days (1 equivalent cy cle) to allow a patient sufficient 
time for recovery  from study  drug -related to xicity.  If a pati ent does not recover from the toxicit y 
within 42 days (2 equivalent cy cles) fro m Day [ADDRESS_1154074] be discont inued fro m study  therapy .
Any procedure or sample collection whose timing is related t o olaratumab dosing is to be 
completed according to when the olaratumab dose was actually administered, not when that dose 
was expected to occur.   Samples whose adjusted timing would fall outside of the treatment cy cle 
durati on due to dose delay  may be om itted.]
7.[ADDRESS_1154075] inhibitors (for example, zoledronic acid or pamidronate) for 
treatm ent of bone m etastases will be permitted while pat ients are on study  treatm ent.  However, 
the osteoclast inhibitor denosumab is a monoclonal antibody  and coul d confound safet y analysis 
in the study  if the patient experiences a hypersensit ivity react ion to denosum ab.  Therefore, 
concomitant use of denosumab will not be permitted.
7.6.1. Evaluable Patients
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 99
LY3012207If the patient is nonco mpliant during olaratumab monotherapy  (Cycle 1) and does not undergo 
the post -olaratum ab m onotherapy  biopsy  or the C1D1 pre -dose and C2D1 predose whole blood 
sample collect ion due to reasons other than drug -related toxicit y, he or she will be consider ed 
nonevaluable for the primary  object ive.  These pat ients may be replaced to ensure that [ADDRESS_1154076] -olaratum ab m onotherapy  biopsy, 
and the associated C2D1 predose whole blood sample co llection.
[IP_ADDRESS].3. Follow -Up Visit
All AEs and SAEs, regardless of relatedness to study  drugs or protocol  procedures, occurring 
during the fo llow-up visit (Visit 801) must be reported t o Lilly  or its designee. The fo llow-up 
visit begins the day  after the pati ent and the invest igator agree that the patient will no longer 
continue study  treatm entstarts following the last dose of study  drug .  At the end of the fo llow-up 
visit, the patient will be requi red to have specific safet y assessments ( Attachment 1).  The timing 
of these safet y assessments is 30 ± [ADDRESS_1154077] dose of study  drug.
[IP_ADDRESS]. Electrocardiograms
Table JGDM. 6provi des Bazett’s QT  heart rate correction formula. Table JGDM.8.3 provides 
Fridericia’s QT correcti on formula for pati ents wi th bundle branch block.
Table JGDM.6. Bazett’s QT Heart Rate Correction Formula
Formula Bazett QTc = QT (HR/60)1/2= QT (RR)–1/[ADDRESS_1154078] HRs
Under-corrects QT at low HRs (the risk of TdP which 
frequently occurs at low HRs, may not be evident)
Abbreviations:  QTc = corrected QT interval; HR = heart rate; RR = duration of ventricular 
cardiac cycle; TdP =torsade de pointes (a polymorphic ventricular 
tachycardia).
Table JGDM 8.3         Fridericia’s QT Corre ction Formula
Formula QTcF=QT/(RR)1/3
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 100
LY3012207Abbreviations:  QT = ECG interval measured from the onset of the QRS complex to the offset
of the T wave; QTcF = QT interval corrected for heart rate using Fridericia’s formula; RR = time between 
corresponding points on 2 consecutive R waves on ECG.
[IP_ADDRESS]. Echocardiograms/MUGA  Scans
An ECHO or MUGA scan is required wit hin 28 days prior to enrollment for all patients.  
Thereafter, ECHO or MUGA scans, whichever technique was used init ially (as described in 
Secti on [IP_ADDRESS].2.2 ), must be performed at the end of Cycles 5 and 7, and when clinically 
indicated.  For patients with LVEF <50% or other cardiac dysfunct ion,perform  more frequent ly, 
if clinically indicated.  After Cy cle 7 (for patients with resting LVEF >≥50%), an ECHO or 
MUGA scan should be obtained at the 30- day follow-up visit (refer to the Study Schedule 
[Attachm ent 1 ]).  
Patients who stop doxorubicin prior to Cy cle 7 (with resti ng LVEF >≥ 50%) will undergo cardiac 
monitoring assessment at the 30 -day follow-up visi t (refer to the Study  Sche dule [ Attachment 1 ]) 
with whichever technique (ECHO or MUGA scan) was used init ially (as described in Sect ion
[IP_ADDRESS].2.2 ).
[IP_ADDRESS]. Tumor Tissue
Collect ion of the fo llowing tum or tissue samples is mandatory  for all  patients:
newly obtained biopsy  specimens taken from  the primary  tumor lesion pre-and post -
olaratum ab m onotherapy  treatment will be collected.  The pretreatment tissue biopsy  is to 
be perform ed wi thin the screening period.  The posttreatment tissue biopsy  is to be 
perform ed after com pletion of the lead -in cycle o f olaratum ab m onothe rapy and pri or to 
the init iation of co mbinat ion therapy  (Cycle 2).  Refer to Attachment 1 for additional 
details.  If clinically  feasible, the bi opsies shoul d be taken fro m the sam e primary tum or 
lesion. 
tumor tissue from  any posttherapy  surgical  resectio n should also be collected and 
provi ded.
Collect ion of the fo llowing tum or tissue samples is optional for all pat ients:
biopsy specimen co llected at the end of the patient’s study  treatm ent.  Refer to 
Attachm ent 1 for addi tional details.  If clinically feasible, this biopsy  should be taken 
from the same primary  tumor lesion.
tumor  tissue fro m any posttherapy  surgical resect ion may also be co llected and provided.  
While this specimen is optional, it is expected this sample will be sent for analysis.
8.[ADDRESS_1154079] cy cle 1 will not be used to determine efficacy .
10.1 General Considerations
I5B-MC-JGDM (c)Phase [ADDRESS_1154080] -olaratumab m onotherapy  biopsy , and the predose C2D1 
whole blood draw. 
If the patient is nonco mpliant during olaratumab monotherapy  (Cycle 1) and do es not undergo 
the pre -treatm ent tissue biopsy, the post -olaratum ab m onotherapy  biopsy, or the pre-dose C1D1 
andpredose C2D1 who le blood draw, he or she will be considered nonevaluable and may be 
replaced.
10.8. Interim Analyses
An interim analysis will b e done to l ook at the biomarker data once approximately half o f the 
evaluable patients com plete the second tum or tissue biopsy and C2D1 who le blood draw.  The 
purpose of this interim analysis is to review the bio marker and safet y data.  If thi s interim l ook at 
the bio marker data warrants any  changes in the study  conduct, i t will  be implemented in an 
appropriate manner (that is, protocol amendment).  Section 10.1 describes the 2 database locks 
and the interim analysis that will occur in this study.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 102
LY3012207Attachment 1. Protocol JGDM Study Schedule
Baseline Schedule of A ctivities
Study Period Baseline
Cycle BL
Visit 0
DurationUp to 14 days
(except where noted)
Relative Day from Enrollment ≤14 ≤[ADDRESS_1154081] be completed ≥4 weeks (28 days) prior to enrollment.
Lab/
Diagnostic 
Tests8.2.3.3 PET ScanX (within 28 days
of enrollment)Within 28 days prior to enrollment.  PET scans will be read locally by [CONTACT_831442] a central vendor where the images will be stored.
Efficacy
Assessment [IP_ADDRESS] PET ScanX (within 28 days
of enrollment)Within 28 days prior to enrollment.  PET scans will be read locally by [CONTACT_831442] a central vendor where the images will be stored.
On-Study -Treatment Schedule of A ctivities
Study Period Treatment Period
Olaratumab
MonotherapyCombination Therapy
Olaratumab + 
Doxorubicin
Cycle (21-day cycle 
± 3 days)1 2-7
Relative Day within 
Cycle 
(± 3 days)1ab8a1ab8a
Procedure 
CategoryProtocol 
SectionProcedure Comments
Lab/
Diagnostic 
Tests8.2.3.[ADDRESS_1154082] be performed at the end of combination 
therapy Cycles 5 and 7 and when clinically indicated .  After Cycle 7, (resting LVEF 
≥>50%), perform echocardiograms or MUGA at the 30 -day follow -up visit.  Patients 
who stop doxorubicin prior to Cycle 7 (with resting LVEF ≥>50%) will undergo the 
same cardiac monitoring assessment. For patients with LVEF <50% or other cardiac 
dysfunction, pe rform more frequently, if clinically indicated.
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 103
LY3012207Study Period Treatment Period
Olaratumab
MonotherapyCombination Therapy
Olaratumab + 
Doxorubicin
Cycle (21-day cycle 
± 3 days)1 2-7
Relative Day within 
Cycle 
(± 3 days)1ab8a1ab8a
Procedure 
CategoryProtocol 
SectionProcedure Comments
Efficacy 
Assessment
Attachment 8Imaging Studies (CT/MRI)
Tumor Assessments 
(according to RECIST 
v1.1)XImaging studies and tumor assessments are tobe obtained every 6 weeks ( ±up to 7 
days before ), irrespective of treatment cycles as calculated from enrollment, until 
documented progression for patients with CR, PR, or SD, and/or for patients who 
have discontinued study treatment due to toxicity or reasons other than PD.  Refer to 
Attachment [ADDRESS_1154083]/MRI scans will be read locally and a scan will also be 
sent for storage at a central vendor.
[IP_ADDRESS] PET Scan XMandatory PET scan must be collected up to [ADDRESS_1154084] dose of C2D1.  
PET scans will be read locally by [CONTACT_831443] a central vendor where 
the images will be stored.
Abbreviations:  β -HCG = beta human chorionic gonadotropin; AE = adverse event; BSA = body surface area; C = cycle; CR = complete response; CRP = clinical research 
physician; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; D =day; DNA = deoxyribonucleic acid; ECG =electrocardiogram; 
ECOG = Eastern Cooperative Oncology Group; eCRF = electronic case report form; IRR = infusion -related reaction; LVEF = left ventricular ejection fraction; MRI = 
magnetic resonance imaging; MUGA = multi -gated acquisition; PD = progressive disease; PET = positron emission tomography; PK = pharmacokinetic; PR = partial response; 
RECIST = Response Evaluation Criteria in Solid Tumors; SD = stable disease; UA = urinalysis.
a Study  procedures will be performed prior to study drug administration, except where noted (such as vital signs).  In case of dose interruption, these evaluations will also 
be done at minimum frequency every 21 days (±3 days).
bRelative day within each cycle ( ≤3 days). Procedure allowed up to 3 days before D1.
Attachment 2. Protocol JGDM Clinical Laboratory Tests
Clinical Chemistry
Serum Concentrations of the following:
Gammaglutamyl transferase
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 104
LY3012207Attachment 4. Protocol JGDM Biomarker, Pharmacokinetic, and Immunogenicity Blood Sampling Schedule 
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 105
LY3012207Cycle DayDosing
Sampling Time (hour) a Olara PK b IGc,dWhole Blood for 
CTC AnalysesPlasma Serum
Doxorubicin Olaratumab
11Within [ADDRESS_1154085] doxorubicin injection X
2 24 hours ± 3 hours X
5 96 hours ± [ADDRESS_1154086] olaratumab infusion X
9 24 hours ± 3 hours X
10 48 hours ± 3 hours X
12 96 hours ± 3 hours X
18 240 hours ± [ADDRESS_1154087] olaratumab infusion X
5, 7 1 Within 15 min before Prior to olaratumab infusion f X X
30-day follow -up Anytime X X XeX X
I5B-MC-JGDM (c)Phase 1 Oncology Protocol Page 106
LY3012207Abbreviations:  CTC = circulating tumor cells; IG = immunogenicity; min = minutes; olara = olaratumab; PK = pharmacokinetic.
aTime 0 is defined as end of infusion.
bSamples of approximately 3 mL of whole blood will be drawn into tubes.  For the olaratumab samples, olaratumab serum PK measurements will be performed.
cSamples of approximately 4 mL will be collected.
dIn addition to the scheduled immunogenicity sampling, in the event of an infusion -related reaction, samples are to be collected as close to the onset of the event as possible, at 
the resolution of the event, and 30 days following the event .
eAt end of the patient’s study treatment .
fPretreatment PK samples may be collected up to [ADDRESS_1154088] be collected prior to administering any premedication.